NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Clinical Guideline Centre (UK). Type 1 Diabetes in Adults: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2015 Aug. (NICE Guideline, No. 17.)

  • July 2016: Recommendation 138 has been reworded to clarify the role of GPs in referring people for eye screening and also to add information on when this should happen.

July 2016: Recommendation 138 has been reworded to clarify the role of GPs in referring people for eye screening and also to add information on when this should happen.

Cover of Type 1 Diabetes in Adults: Diagnosis and Management

Type 1 Diabetes in Adults: Diagnosis and Management.

Show details

17Reference list

1.
Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. American Journal of Medicine. 1991;90(4):450–459. [PubMed: 2012085]
2.
Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18(3):361–376. [PubMed: 7555480]
3.
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983. [PubMed: 7622004]
4.
The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289–1298. [PubMed: 8826962]
5.
Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46(2):271–286. [PubMed: 9000705]
6.
Assessing the benefit of support groups. New England Journal of Medicine. 2001;345(24):1719–1726. 1767–68. [PubMed: 11742045]
7.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997. [PubMed: 12479763]
8.
The DAWN (Diabetes Attitudes, Wishes and Needs) study. Practical Diabetes International. 2002;19(1):22a–24a.
9.
MIMS. 2013. [12 December 2013]. Available from: http://www​.mims.co.uk/
10.
A'Campo T, Schouwenberg B, Veldman B, Tack CJ, Smits P, de Galan BE. Prevalence and risk factors of hypoglycaemia unawareness and severe hypoglycaemia in patients with type 1 diabetes. Diabetologia. 2010;53(Suppl.1):S239.
11.
Abdelgadir M, Elbagir M, Eltom M, Berne C. The influence of glucose self-monitoring on glycaemic control in patients with diabetes mellitus in Sudan. Diabetes Research and Clinical Practice. 2006;74(1):90–94. [PubMed: 16621118]
12.
Abelev Z, Seth A, Patel R, Goldstein S, Bogun M, Paliou M, et al. Continuous insulin infusion is associated with a reduced post-surgical length of stay, but not with the complication rate, in patients with diabetes mellitus undergoing coronary artery bypass graft. Journal of Endocrinological Investigation. 2011;34(10):770–774. [PubMed: 21623155]
13.
Abell T, Mccallum RW, Hocking M, Koch K, Abrahamsson H, Leblanc I, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125(2):421–428. [PubMed: 12891544]
14.
Abell TL, Johnson WD, Kedar A, Runnels JM, Thompson J, Weeks ES, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointestinal Endoscopy. 2011;74(3):496. [PMC free article: PMC5098698] [PubMed: 21872708]
15.
Adamson CL, Kumar S, Sutcliffe H, France MW, Boulton AJM. Screening strategies in the detection of microalbuminuria in insulin-dependent diabetic patients. Practical Diabetes. 1993;10(4):142–144.
16.
Adamson KA, Hassanein M, Malik I, White H, Vora J. Short or intermittent use of continuous glucose monitoring (CGM) enhances glycaemic control in subjects with persistently poorly controlled diabetes. Diabetic Medicine. 2013;30(Suppl.1):160.
17.
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–419. [PMC free article: PMC27455] [PubMed: 10938049]
18.
AETMIS. Montreal. Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2002. Screening for diabetic retinopathy: validation of a system using telemedicine approach- primary research (project) Available from: http://www​.aetmis.gouv.qc.ca.
19.
Affenito SG, Kerstetter J. Position of the American Dietetic Association and Dietitians of Canada: women's health and nutrition. Journal of the American Dietetic Association. 1999;99(6):738–751. [PubMed: 10361541]
20.
Agardh CD. A new semiquantitative rapid test for screening for microalbuminuria. Practical Diabetes. 1993;10(4):146–147.
21.
Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Research and Clinical Practice. 1997;35(2-3):113–121. [PubMed: 9179466]
22.
Aggarwal S, Goel A, Jain A. Role of C- peptide in identification of patients suspected of having latent autoimmune diabetes in adults (LADA) in north Indian type 2 diabetes mellitus population. International Journal of Pharma and Bio Sciences. 2010;1(3)
23.
Ahn CW, Song YD, Kim JH, Lim SK, Choi KH, Kim KR, et al. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Medical Journal. 1999;40(1):40–45. [PubMed: 10198605]
24.
Aiello LP. DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):17–23. [PMC free article: PMC3867989] [PubMed: 24356593]
25.
Allen C, LeCaire T, Palta M, Daniels K, Meredith M, D'Alessio DJ, et al. Risk factors for frequent and severe hypoglycemia in type 1 diabetes. Diabetes Care. 2001;24(11):1878–1881. [PubMed: 11679450]
26.
Allen S, Huber J, Devendra D. Prevalence of organ-specific autoantibodies in childhood- and adult-onset type 1 diabetes. Annals of the New York Academy of Sciences. 2008;1150:260–262. [PubMed: 19120308]
27.
Alloway SC, Toth EL, McCargar LJ. Effectiveness of a group psychoeducation program for the treatment of subclinical disordered eating in women with type 1 diabetes. Canadian Journal of Dietetic Practice and Research. 2001;62(4):188–192. [PubMed: 11742560]
28.
Almdal T, Norgaard K, Feldt-Rasmussen B, Deckert T. The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care. 1994;17(2):120–125. [PubMed: 8137681]
29.
American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl.1):S33–S50. [PubMed: 12502618]
30.
American Healthways. Inpatient management guidelines for people with diabetes. Nashville, Tennessee: American Healthways; 2002.
31.
Amiel S, Beveridge S, Bradley C, Gianfrancesco C, Heller S, James P, et al. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746–749. [PMC free article: PMC128375] [PubMed: 12364302]
32.
Amrouche C, Jamoussi Kamoun H, Trabelsi N, Blouza Chabchoub S. Latent autoimmune diabetes in Tunisian adults (LADA): identification of autoimmune markers. La Tunesie Medicale. 2008;86(4):316–318. [PubMed: 19476130]
33.
Andersen MK, Sterner M, Forsen T, Karajamaki A, Rolandsson O, Forsblom C, et al. Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes. Diabetologia. 2014;57(9):1859–1868. [PubMed: 24906951]
34.
Anderson JH Jr., Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265–270. [PubMed: 9000704]
35.
Anderson JW, Zeigler JA, Deakins DA, Floore TL, Dillon DW, Wood CL, et al. Metabolic effects of high-carbohydrate, high-fiber diets for insulin-dependent diabetic individuals. American Journal of Clinical Nutrition. 1991;54(5):936–943. [PubMed: 1659172]
36.
Anderson J, Brunelle RL, Trautmann ME, Vignati L, DiMarchi R, Cameron DP, et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics. 1997;19(1):62–72. [PubMed: 9083709]
37.
Anderson RJ, de Groot M, Grigsby AB, McGill JB, Freedland KE, Clouse RE, et al. Anxiety and poor glycemic control: a meta-analytic review of the literature. International Journal of Psychiatry in Medicine. 2002;32(3):235–247. [PubMed: 12489699]
38.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–1078. [PubMed: 11375373]
39.
Annuzzi G, Del PS, Arcari R, Bellomo DA, Benzi L, Bruttomesso D, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutrition, Metabolism, and Cardiovascular Diseases. 2001;11(3):168–175. [PubMed: 11590992]
40.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. [PMC free article: PMC64503] [PubMed: 11786451]
41.
Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J. Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation. Journal of Internal Medicine. 1994;235(5):463–471. [PubMed: 8182403]
42.
Araszkiewicz A, Zozulinska DA, Trepinska MM, Wierusz-Wysocka B. Inflammatory markers as risk factors for microangiopathy in type 1 diabetic patients on functional intensive insulin therapy from the onset of the disease. Diabetes Research and Clinical Practice. 2006;74(2 Suppl.):S34–S40.
43.
Araszkiewicz A, Zozulinska-Ziolkiewicz DA, Trepinska M, Wierusz-Wysocka B. Why does intensive insulin therapy implemented at the onset of type 1 diabetes not decrease prevalence of diabetic microangiopathy? Archives of Medical Research. 2008;4(2):167–173.
44.
Arikan E, Sabuncu T, Ozer EM, Hatemi H. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus. Journal of Diabetes and Its Complications. 2005;19(5):254–258. [PubMed: 16112499]
45.
Aronson R, Gibney MA, Oza K, Berube J, Kassler-Taub K, Hirsch L. Insulin pen needles: Effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clinical Therapeutics. 2013;35(7):923–933. [PubMed: 23790553]
46.
Arora S, Probst MA, Agy C, Menchine M. Point-of-care beta-hydroxybutyrate testing for assessing diabetic ketoacidosis severity prior to treatment in the emergency department. Diabetes Research and Clinical Practice. 2011;94(3):e86–e88. [PubMed: 21955959]
47.
Arora S, Henderson SO, Long T, Menchine M. Diagnostic accuracy of point-of-care testing for diabetic ketoacidosis at emergency-department triage: {beta}-hydroxybutyrate versus the urine dipstick. Diabetes Care. 2011;34(4):852–854. [PMC free article: PMC3064039] [PubMed: 21307381]
48.
Arslan D, Merdin A, Tural D, Temizel M, Akin O, Gunduz S, et al. The effect of autoimmunity on the development time of microvascular complications in patients with type 1 diabetes mellitus. Medical Science Monitor. 2014;20:1176–1179. [PMC free article: PMC4103811] [PubMed: 25007947]
49.
Asakura T, Seino H, Nunoi K, Hashimoto K, Mutou T, Yamazaki K, et al. Usability of a microtapered needle (TN3305) for insulin treatment in Japanese patients with diabetes mellitus: a comparative clinical study with a standard thin wall needle. Diabetes Technology and Therapeutics. 2006;8(4):489–494. [PubMed: 16939373]
50.
Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine. 2006;23(3):285–292. [PubMed: 16492212]
51.
Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabetic Medicine. 2006;23(8):879–886. [PubMed: 16911626]
52.
Aspinall SL, Smith KJ, Cunningham FE, Good CB. Incremental cost-effectiveness of various monthly doses of vardenafil. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2011;14(1):97–101. [PubMed: 21211491]
53.
Assal JP, Jacquemet S, Morel Y. The added value of therapy in diabetes: the education of patients for self-management of their disease. Metabolism: Clinical and Experimental. 1997;46(12 Suppl.1):61–64. [PubMed: 9439562]
54.
Athyros VG, Didangelos TP, Karamitsos DT, Papageorgiou AA, Boudoulas H, Kontopoulos AG. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. Acta Cardiologica. 1998;53(4):201–209. [PubMed: 9842405]
55.
Azzopardi J, Fenech FF, Junoussov Z, Mazovetsky A, Olchanski V. A computerized health screening and follow-up system in diabetes mellitus. Diabetic Medicine. 1995;12(3):271–276. [PubMed: 7758266]
56.
Bailey BJ, Kahn A. Apportioning illness management authority: how diabetic individuals evaluate and respond to spousal help. Qualitative Health Research. 1993;3(1):55–73. [PubMed: 8457792]
57.
Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16(12):1592–1597. [PubMed: 8299455]
58.
Bao J, Gilbertson HR, Gray R, Munns D, Howard G, Petocz P, et al. Improving the estimation of mealtime insulin dose in adults with type 1 diabetes: the Normal Insulin Demand for Dose Adjustment (NIDDA) study. Diabetes Care. 2011;34(10):2146–2151. [PMC free article: PMC3177729] [PubMed: 21949219]
59.
Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, et al. Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obesity and Metabolism. 2014;16(3):262–267. [PubMed: 24118704]
60.
Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Medicine. 2008;25(4):442–449. [PMC free article: PMC2327220] [PubMed: 18387078]
61.
Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012;35(7):1436–1445. [PMC free article: PMC3379615] [PubMed: 22723582]
62.
Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55(12):3155–3162. [PMC free article: PMC3483098] [PubMed: 22965294]
63.
Bayly GR, Bartlett WA, Davies PH, Husband D, Haddon A, Game FL, et al. Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic. Diabetic Medicine. 1999;16(8):697–701. [PubMed: 10477217]
64.
Beck RW, Lawrence JM, Laffel L, Wysocki T, Xing D, Huang ES, et al. Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care. 2010;33(10):2175–2177. [PMC free article: PMC2945155] [PubMed: 20696865]
65.
Beik N, Anger KE, Forni AA, Bawa K, Szumita PM. Evaluation of an institution-wide guideline for hyperglycemic emergencies at a tertiary academic medical center. Annals of Pharmacotherapy. 2013;47(10):1260–1265. [PubMed: 24259689]
66.
Bektas F, Eray O, Sari R, Akbas H. Point of care blood ketone testing of diabetic patients in the emergency department. Endocrine Research. 2004;30(3):395–402. [PubMed: 15554356]
67.
Bell DS, Cutter G. Characteristics of severe hypoglycemia in the patient with insulin-dependent diabetes. Southern Medical Journal. 1994;87(6):616–620. [PubMed: 8202770]
68.
Bell DSH, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. American Journal of Therapeutics. 2004;11(4):308–311. [PubMed: 15266224]
69.
Bell PM, Walshe K. Home blood glucose monitoring. Impact on lifestyle and diabetes control. Practitioner. 1984;228(1388):197–202. [PubMed: 6701149]
70.
Berlin I, Bisserbe JC, Eiber R, Balssa N, Sachon C, Bosquet F, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care. 1997;20(2):176–178. [PubMed: 9118768]
71.
Berlin I, Sachon CI, Grimaldi A. Identification of factors associated with impaired hypoglycaemia awareness in patients with type 1 and type 2 diabetes mellitus. Diabetes & Metabolism. 2005;31(3 Pt.1):246–251. [PubMed: 16142015]
72.
Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care. 2011;34(3):607–609. [PMC free article: PMC3041191] [PubMed: 21285386]
73.
Bianchi G, Montanari P, Fabbri A, Gamberini A, Zoli M, Marchesini G. Thyroid volume in type 1 diabetes patients without overt thyroid disease. Acta Diabetologica. 1995;32(1):49–52. [PubMed: 7612918]
74.
Biermann E, Dietrich W, Rihl J, Standl E. Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial. Computer Methods and Programs in Biomedicine. 2002;69(2):137–146. [PubMed: 12100793]
75.
Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care. 2008;31(9):e65. [PubMed: 18753661]
76.
Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661–665. [PMC free article: PMC3041203] [PubMed: 21270174]
77.
Bjorvig S, Johansen MA, Fossen K. An economic analysis of screening for diabetic retinopathy. Journal of Telemedicine and Telecare. 2002;8(1):32–35. [PubMed: 11809082]
78.
Bodalska-Lipinska J, Szadkowska A, Markuszewski L. Principles of diagnosis of latent autoimmune diabetes in adults (LADA). Diabetologia Doswiadczalna i Kliniczna. 2006;6(2):69–74.
79.
Bode B, Hirsch IB. Sustained reduction of biochemical, clinical and severe hypoglycaemia with extended CGM use: Results of JDRF CGM six month extension study. Diabetologia. 2009;52(S1):S235.
80.
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal–bolus Type 1): 2-year results of a randomized clinical trial. Diabetic Medicine. 2013;30(11):1293–1297. [PMC free article: PMC4264937] [PubMed: 23710902]
81.
Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabetic Medicine. 2002;19(5):393–399. [PubMed: 12027927]
82.
Bolli GB, Songini M, Trovati M, Prato S, Ghirlanda G, Cordera R, et al. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with type 1 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases. 2009;19(8):571–579. [PubMed: 18676131]
83.
Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ. 1993;306(6894):1722–1725. [PMC free article: PMC1678304] [PubMed: 8343628]
84.
Borg H, Arnqvist HJ, Bjork E, Bolinder J, Eriksson JW, Nystrom L, et al. Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2003;46(2):173–181. [PubMed: 12627315]
85.
Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetic Medicine. 2003;20(8):626–634. [PubMed: 12873289]
86.
Bott U, Jorgens V, Grusser M, Bender R, Muhlhauser I, Berger M. Predictors of glycaemic control in type 1 diabetic patients after participation in an intensified treatment and teaching programme. Diabetic Medicine. 1994;11(4):362–371. [PubMed: 8088108]
87.
Bottazzo GF, Bosi E, Cull CA, Bonifacio E, Locatelli M, Zimmet P, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia. 2005;48(4):703–708. [PubMed: 15765222]
88.
Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia. 2001;44(10):1296–1301. [PubMed: 11692178]
89.
Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia. 2001;44(10):1296–1301. [PubMed: 11692178]
90.
Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male : the Official Journal of the International Society for the Study of the Aging Male. 2003;6(1):1–7. [PubMed: 12809074]
91.
Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male : the Official Journal of the International Society for the Study of the Aging Male. 2003;6(1):1–7. [PubMed: 12809074]
92.
Bragd J, Adamson U, Lins PE, Wredling R, Oskarsson P. A repeated cross-sectional survey of severe hypoglycaemia in 178 Type 1 diabetes mellitus patients performed in 1984 and 1998. Diabetic Medicine. 2003;20(3):216–219. [PubMed: 12675666]
93.
Braid E, Campbell B, Curtis S, Eden G, Keast T, Hardcastle S, et al. The diabetes Annual Review as an educational tool: assessment and learning integrated with care, screening, and audit. Diabetic Medicine. 1992;9(4):389–394. [PubMed: 1600714]
94.
Braun AP. Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients. Advances in Therapy. 1989;(6):51–62.
95.
Brazeau AS, Mircescu H, Desjardins K, Leroux C, Strychar I, Ekoe JM, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Research and Clinical Practice. 2013;99(1):19–23. [PubMed: 23146371]
96.
Bridgford A, Davis TME. A comprehensive patient-held record for diabetes. Part one: initial development of the Diabetes Databank. Practical Diabetes International. 2001;18(7):241–245.
97.
Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ. 1992;304(6818):19–22. [PMC free article: PMC1880908] [PubMed: 1734985]
98.
Brink SJ, Miller M, Moltz KC. Education and multidisciplinary team care concepts for pediatric and adolescent diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism. 2002;15(8):1113–1130. [PubMed: 12387509]
99.
Brock JI, Vind BF, Korsholm L, Flyvbjerg A, Frystyk J, Holst JJ, et al. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin aspart or human soluble insulin: a double-blinded randomized cross-over study. Acta Physiologica. 2011;202(3):337–347. [PubMed: 21481195]
100.
Brooks AM, Walker N, Aldibbiat A, Hughes S, Jones G, de Havilland J, et al. Attainment of metabolic goals in the integrated UK Islet Transplant Program with locally isolated and transported preparations. American Journal of Transplantation. 2013;13(12):3236–3243. [PubMed: 24119216]
101.
Brunetti P, Muggeo M, Cattin L, Arcangeli A, Pozzilli P, Provenzano V, et al. Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine. Nutrition, Metabolism, and Cardiovascular Diseases. 2010;20(7):519–526. [PubMed: 19703761]
102.
Brunova J, Bruna J, Koning M, Meyer M, Joubert G, Mollentze W. GAD65Ab and primary hypothyroidism in type 1 and 2 diabetic subjects. Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2002;7(1):6–8.
103.
Bruttomesso D, Barberio S, Fongher C, Lisato G, Silvestri B, Briani G, et al. Retrospective analysis of daily glucose profile in type 1 diabetic patients with continuous subcutaneous insulin infusion (CSII). Diabetes Research and Clinical Practice. 1992;16(3):197–202. [PubMed: 1425140]
104.
Bryden KS, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Journal of Psychosomatic Research. 1999;22(12):1956–1960. [PubMed: 10587825]
105.
Burchardt P, Zawada A, Tabaczewski P, Naskret D, Kaczmarek J, Marcinkaniec J, et al. Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low-density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. Polskie Archiwum Medycyny Wewnetrznej. 2013;123(10):526–532. [PubMed: 23928867]
106.
Burnett SD, Press M, Yudkin JS. Compiling a district diabetic register: theoretical and practical considerations. Diabetic Medicine. 1993;10(3):199–200. [PubMed: 8485951]
107.
Burnett SD, Woolf CM, Yudkin JS. Developing a district diabetic register. BMJ. 1992;305(6854):627–630. [PMC free article: PMC1883368] [PubMed: 1294089]
108.
Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care. 1999;22(8):1245–1251. [PubMed: 10480765]
109.
Bursell SE, Brazionis L, Jenkins A. Telemedicine and ocular health in diabetes mellitus. Clinical and Experimental Optometry. 2012;95(3):311–327. [PubMed: 22594547]
110.
Buvat J, van AH, Schmitt H, Chan M, Kuepfer C, Varanese L. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. Journal of Sexual Medicine. 2006;3(3):512–520. [PubMed: 16681477]
111.
Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999;22(11):1785–1789. [PubMed: 10546008]
112.
Calle-Pascual AL, Gomez V, Leon E, Bordiu E. Foods with a low glycemic index do not improve glycemic control of both type 1 and type 2 diabetic patients after one month of therapy. Diabetes & Metabolism. 1988;14(5):629–633. [PubMed: 3234586]
113.
Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Canadian Medical Association Journal. 2009;180(4):400–407. [PMC free article: PMC2638053] [PubMed: 19221353]
114.
Canadian Agency for Drugs and Technologies in Health. An economic evaluation of insulin analogues for the treatment of patients with type 1 and type 2 diabetes mellitus in Canada. COMPUS. 2008;2(4):1–52.
115.
Cardoso C, Ohwovoriole AE, KuKu SF. A study of thyroid function and prevalence of thyroid autoantibodies in an African diabetic population. Journal of Diabetes and Its Complications. 1995;9(1):37–41. [PubMed: 7734742]
116.
Castleden HAJ, Shields B, Bingley PJ, Williams AJK, Sampson M, Walker M, et al. GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. Diabetic Medicine. 2006;23(8):834–838. [PubMed: 16911619]
117.
Cavan DA, Hamilton P, Everett J, Kerr D. Reducing hospital inpatient length of stay for patients with diabetes. Diabetic Medicine. 2001;18(2):162–164. [PubMed: 11251683]
118.
Cerna M, Novota P, Kolostova K, Cejkova P, Zdarsky E, Novakova D, et al. HLA in Czech adult patients with autoimmune diabetes mellitus: comparison with Czech children with type 1 diabetes and patients with type 2 diabetes. European Journal of Immunogenetics. 2003;30(6):401–407. [PubMed: 14675393]
119.
Chan JCN, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SRG, Hancu N, et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009;32(2):227–233. [PMC free article: PMC2628684] [PubMed: 19033410]
120.
Chan WB, Chow CC, Yeung VTF, Chan JCN, So WY, Cockram CS. Effect of insulin lispro on glycaemic control in Chinese diabetic patients receiving twice-daily regimens of insulin. Chinese Medical Journal. 2004;117(9):1404–1407. [PubMed: 15377436]
121.
Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal–bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Research and Clinical Practice. 2007;77(2):215–222. [PubMed: 17141354]
122.
Chen JW, Lauritzen T, Bojesen A, Christiansen JS. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal–bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obesity and Metabolism. 2006;8(6):682–689. [PubMed: 17026493]
123.
Chiarelli F, Verrotti A, Di Ricco L, LaPorte RE. Information superhighway, Internet and diabetes. Diabetes, Nutrition and Metabolism - Clinical and Experimental. 1998;11(4):219–224.
124.
Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26(4):1153–1157. [PubMed: 12663589]
125.
Choudhary P, Davies C, Emery CJ, Heller SR. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact? Diabetic Medicine. 2013;30(8):914–917. [PubMed: 23672623]
126.
Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabetic Medicine. 2010;27(6):666–672. [PubMed: 20546285]
127.
Choudhary P, Parrott NR, Birtles L, Rutter MK. Islet cell transplantation: current status in the UK. Practical Diabetes. 2012;29(7):280–285.
128.
Choudhary P, Ramasamy S, Green L, Gallen G, Pender S, Brackenridge A, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 2013;36(12):4160–4162. [PMC free article: PMC3836107] [PubMed: 24103902]
129.
Chowta MN, Adhikari PM, Chowta NK, Shenoy AK, D'Souza S. Serum C peptide level and renal function in diabetes mellitus. Indian Journal of Nephrology. 2010;20(1):25–28. [PMC free article: PMC2878407] [PubMed: 20535267]
130.
Christiansen CL, Schurizek BA, Malling B, Knudsen L, Alberti KG, Hermansen K. Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration. Anaesthesia. 1988;43(7):533–537. [PubMed: 3046411]
131.
Christiansen M, Bailey T, Watkins E, Liljenquist D, Price D, Nakamura K, et al. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technology and Therapeutics. 2013;15(10):881–888. [PMC free article: PMC3781114] [PubMed: 23777402]
132.
Ciavarella A, Silletti A, Forlani G, Morotti L, Borgnino LC, D'Apote M, et al. A screening test for microalbuminuria in type 1 (insulin-dependent) diabetes. Diabetes Research and Clinical Practice. 1989;7(4):307–312. [PubMed: 2612345]
133.
Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care. 1999;22(5):795–800. [PubMed: 10332684]
134.
Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Canadian Medical Association Journal. 2000;162(2):195–198. [PMC free article: PMC1232268] [PubMed: 10674051]
135.
Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18(4):517–522. [PubMed: 7497862]
136.
Clinical Immunology Service. Laboratory handbook and price list; a brief guide for clinical and laboratory staff. Birmingham. University of Birmingham, School of Immunity & Infection, College of Medical and Dental Sciences; 2010. Available from: www​.uhb.nhs.uk/pdf/laboratoryhandbookuob.pdf.
137.
Close N, Alejandro R, Hering B, Appel M. Second annual analysis of the collaborative islet transplant registry. Transplantation Proceedings. 2007;39(1):179–182. [PMC free article: PMC2720061] [PubMed: 17275500]
138.
Collaborative Islet Transplant Registry Coordinating Registry. Collaborative Islet Transplant Registry seventh annual report. Collaborative Islet Transplant Registry. 2011. Available from: https://web​.emmes.com​/study/isl//reports​/01062012_7thAnnualReport.pdf.
139.
Collier A, Steedman DJ, Patrick AW, Nimmo GR, Matthews DM, Macintyre CCA, et al. Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care. 1987;10(6):712–715. [PubMed: 3428048]
140.
Collins AC, Vincent J, Newall RG, Mitchell KM, Viberti GC. An aid to the early detection and management of diabetic nephropathy: assessment of a new point of care microalbuminuria system in the diabetic clinic. Diabetic Medicine. 2001;18(11):928–932. [PubMed: 11703439]
141.
Collins JE, Heward JM, Nithiyananthan R, Nejentsev S, Todd JA, Franklyn JA, et al. Lack of association of the vitamin D receptor gene with Graves' disease in UK Caucasians. Clinical Endocrinology. 2004;60(5):618–624. [PubMed: 15104566]
142.
Connell CM, Davis WK, Gallant MP, Sharpe PA. Impact of social support, social cognitive variables, and perceived threat on depression among adults with diabetes. Health Psychology. 1994;13(3):263–273. [PubMed: 8055861]
143.
Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 1993;16(10):1376–1383. [PubMed: 8269796]
144.
Cooper JG, Mathieu C, Hollander P, Miranda-Palma B, Franek E, Bain S, et al. Insulin degludec allows for flexible daily dosing in type 1 diabetes, providing equal glycaemic control with less nocturnal hypoglycaemia than insulin glargine over 52 weeks. Diabetologia. 2012;55(Suppl.1):S374.
145.
Corney SM, Dukatz T, Rosenblatt S, Harrison B, Murray R, Sakharova A, et al. Comparison of insulin pump therapy (continuous subcutaneous insulin infusion) to alternative methods for perioperative glycemic management in patients with planned postoperative admissions. Journal of Diabetes Science and Technology. 2012;6(5):1003–1015. [PMC free article: PMC3570833] [PubMed: 23063025]
146.
Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training-II. Diabetes Care. 1995;18(4):523–528. [PubMed: 7497863]
147.
Cox DJ, Gonder-Frederick L, Polonsky W, Schlundt D, Kovatchev B, Clarke W. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care. 2001;24(4):637–642. [PubMed: 11315822]
148.
Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. Journal of Clinical Endocrinology and Metabolism. 1994;79(6):1659–1662. [PubMed: 7989471]
149.
Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care. 2007;30(6):1370–1373. [PubMed: 17363757]
150.
Cox DJ, Kovatchev B, Koev D, Koeva L, Dachev S, Tcharaktchiev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. International Journal of Behavioral Medicine. 2004;11(4):212–218. [PubMed: 15657021]
151.
Cox R, Beaven DW, Helm AM. Home monitoring of blood glucose: a retrospective assessment in 38 insulin-requiring diabetics. New Zealand Medical Journal. 1980;92(667):193–196. [PubMed: 6933357]
152.
Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344(8918):283–287. [PubMed: 7914259]
153.
Crijns H, Casparie AF, Hendrikse F. Continuous computer simulation analysis of the cost-effectiveness of screening and treating diabetic retinopathy. International Journal of Technology Assessment in Health Care. 1999;15(1):198–206. [PubMed: 10407606]
154.
Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care. 2012;35(9):1814–1816. [PMC free article: PMC3425013] [PubMed: 22923682]
155.
Cucinotta D, Mannino D, Lasco A, Di Cesare E, Musolino C, Alessi R. Premixed insulin at ratio 3/7 and regular + isophane insulins at mixing ratios from 2/8 to 4/6 achieve the same metabolic control. Diabetes & Metabolism. 1991;17(1):49–54. [PubMed: 1868960]
156.
Cummings DM, Morrissey S, Barondes MJ, Rogers L, Gustke S. Screening for diabetic retinopathy in rural areas: the potential of telemedicine. Journal of Rural Health. 2001;17(1):25–31. [PubMed: 11354719]
157.
Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion. 2006;22(8):1523–1534. [PubMed: 16870077]
158.
Curtis L. Unit costs of health and social care 2011. Canterbury: Personal Social Services Research Unit, University of Kent; 2012. Available from: http://www​.pssru.ac.uk​/project-pages/unit-costs/2011/
159.
Curtis L. Unit costs of health and social care 2012. Canterbury: Personal Social Services Research Unit, University of Kent; 2012. Available from: http://www​.pssru.ac.uk​/project-pages/unit-costs/2012/
160.
Czyzewska K, Czerniawska E, Szadkowska A. Prevalence of hypoglycemia unawareness in patients with type 1 diabetes. Pediatric Diabetes. 2012;13(S17):77.
161.
Dagdelen S, Hascelik G, Bayraktar M. Simultaneous triple organ specific autoantibody profiling in adult patients with type 1 diabetes mellitus and their first-degree relatives. International Journal of Clinical Practice. 2009;63(3):449–456. [PubMed: 18218004]
162.
Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. Journal of Clinical Investigation. 1993;91(3):819–828. [PMC free article: PMC288033] [PubMed: 8450063]
163.
Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: The Oslo study. BMJ. 1985;290(6471):811–815. [PMC free article: PMC1418598] [PubMed: 3919804]
164.
Dargis V, Pantelejeva O, Jonushaite A, Vileikyte L, Boulton AJ. Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study. Diabetes Care. 1999;22(9):1428–1431. [PubMed: 10480504]
165.
Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics. 1998;13(3):347–358. [PubMed: 10178660]
166.
Davies H, Brophy S, Fielding A, Bingley P, Chandler M, Hilldrup I, et al. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization. Diabetic Medicine. 2008;25(11):1354–1357. [PubMed: 19046228]
167.
Davies M, Dixon S, Currie CJ, Davis RE, Peters JR. Evaluation of a hospital diabetes specialist nursing service: a randomized controlled trial. Diabetic Medicine. 2001;18(4):301–307. [PubMed: 11437861]
168.
Davis RE, McCann VJ, Stanton KG. Type 1 diabetes and latent pernicious anaemia. Medical Journal of Australia. 1992;156(3):160–162. [PubMed: 1545717]
169.
Davis TME, Bridgford A. A comprehensive patient-held record for diabetes. Part two: Large-scale assessment of the diabetes databank by patients and health care workers. Practical Diabetes International. 2001;18(9):311–314.
170.
Davis TME, Holman RR, Eaton PM, Turner RC. A regular meal and insulin infusion regimen: Its use in the treatment of acute-onset ketotic diabetes and in stabilization of poorly controlled established diabetic subjects. Diabetes Care. 1982;5(5):492–496. [PubMed: 6821354]
171.
Davis TME, Mehta Z, Mackay IR, Cull CA, Bruce DG, Fida S, et al. Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes. Diabetic Medicine. 2003;20(3):198–204. [PubMed: 12675663]
172.
Day JL, Metcalfe J, Johnson P. Benefits provided by an integrated education and clinical diabetes centre: a follow-up study. Diabetic Medicine. 1992;9(9):855–859. [PubMed: 1473327]
173.
de Weerdt I, Visser AP, Kok GJ, de Weerdt O, van der Veen EA. Randomized controlled multicentre evaluation of an education programme for insulin-treated diabetic patients: effects on metabolic control, quality of life, and costs of therapy. Diabetic Medicine. 1991;8(4):338–345. [PubMed: 1830257]
174.
de Zoysa N, Rogers H, Stadler M, Gianfrancesco C, Beveridge S, Britneff E, et al. A psychoeducational program to restore hypoglycemia awareness: The DAFNE-HART pilot study. Diabetes Care. 2014;37(3):863–866. [PubMed: 24319119]
175.
Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730–2732. [PubMed: 17130215]
176.
Delahanty L, Simkins SW, Camelon K. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. The DCCT Research Group. Journal of the American Dietetic Association. 1993;93(7):758–64. 767. [PubMed: 8320401]
177.
Department of Health. NHS reference costs 2011-12. 2012. [7 October 2014]. Available from: https://www​.gov.uk/government​/publications​/nhs-reference-costs-financial-year-2011-to-2012.
178.
Department of Veterans Affairs. The management of diabetes mellitus in the primary care setting. Washington (DC): Department of Veterans Affairs; 1999.
179.
Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E, Lampasona V, et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia. 2007;50(10):2052–2060. [PubMed: 17657474]
180.
Desautels SG, Hutson WR, Christian PE, Moore JG, Datz FL. Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesis. Digestive Diseases and Sciences. 1995;40(1):141–146. [PubMed: 7821102]
181.
Deyoung L, Chung E, Kovac JR, Romano W, Brock GB. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. Journal of Andrology. 2012;33(2):176–180. [PubMed: 21680809]
182.
Dhatariya K, Levy N, Kilvert A, Watson B, Cousins D, Flanagan D, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabetic Medicine. 2012;29(4):420–433. [PubMed: 22288687]
183.
Diabetes UK. Recommendations for the management of diabetes in primary care. 2000. Available from: http://www​.diabetes.org​.uk/infocentre/carerec/primary.htm.
184.
Diabetes UK. Carbs count: an introduction to carbohydrate counting and insulin dose adjustment. 2011. Available from: https://shop​.diabetes​.org.uk/usr/downloads​/A%20Carbs-Count-2012-reducedsize.pdf.
185.
Diabetes UK. Evidence-based nutrition guidelines for the prevention and management of diabetes. London: Diabetes UK; 2011. Available from: http://www​.diabetes.org​.uk/Documents/Reports​/Nutritional_guidelines200911.pdf.
186.
Diabetes UK and Care Interventions Team. Needs of the recently diagnosed. Diabetes UK; 2001. Listening project. Report and recommendations.
187.
Diamante E. Renal involvement in type 1 (IDDM) diabetes in Spain. Diabetes Research and Clinical Practice. 1997;38(2):129–137. [PubMed: 9483377]
188.
Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 2011. Available from: http://www​.nicedsu.org.uk. [PubMed: 27466656]
189.
Dias VM, Pandini JA, Nunes RR, Sperandei SL, Portella ES, Cobas RA, et al. Effect of the carbohydrate counting method on glycemic control in patients with type 1 diabetes. Diabetology and Metabolic Syndrome. 2010;2:54. [PMC free article: PMC2933609] [PubMed: 20716374]
190.
Didangelos T, Anastasiou E, Vasilopoulos C, Zoupas C, Manes C, Tsatsoulis A, et al. Improvement of metabolic control after three months of RT-CGM in type 1 diabetics with CSII. Diabetes Multicenter Observational Study (DIAMOND). Diabetes Technology and Therapeutics. 2014;16(S1):A14–A15.
191.
Didangelos TP, Karamitsos DT, Athyros VG, Kourtoglou GI. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. Journal of Diabetes & Its Complications. 1998;12(4):201–207. [PubMed: 9647338]
192.
Dinneen SF, O'Hara MC, Byrne M, Smith D, Courtney CH, McGurk C, et al. Group follow-up compared to individual clinic visits after structured education for type 1 diabetes: a cluster randomised controlled trial. Diabetes Research and Clinical Practice. 2013;100(1):29–38. [PubMed: 23398978]
193.
Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach. Pharmacoeconomics. 2000;18(3):275–287. [PubMed: 11147394]
194.
Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Hormone and Metabolic Research. 2005;37(11):702–707. [PubMed: 16308840]
195.
Dufaitre-Patouraux L, Riveline JP, Renard E, Melki V, Belicar-Schaepelynck P, Selam JL, et al. Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study. Diabetes & Metabolism. 2006;32(5 Pt.1):427–432. [PubMed: 17110897]
196.
Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care. 1994;17(8):874–878. [PubMed: 7956634]
197.
Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189–2195. [PubMed: 17003291]
198.
Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care. 2010;33(7):1640–1646. [PMC free article: PMC2890374] [PubMed: 20424222]
199.
Eli Lilly and Company. Clinical study summary: study F3Z-MC-IOAA(b). LY275585 vs. Humulin R: premeal therapy in type 1 diabetes. 1994.
200.
Eli Lilly and Company. Clinical study summary: study F3Z-MC-IOAC(b). LY275585 vs. Humulin R: premeal therapy in type 1 diabetes. 1995.
201.
Eli Lilly and Company. Clinical study summary: study F3Z-MC-IOAE. LY275585 vs. Humulin R: premeal therapy in new patients with type 1 diabetes. 1995.
202.
Eli Lilly and Company. Clinical study summary: study F3Z-MC-IOAG. LY275585 vs. Humulin R: premeal therapy in type 1 diabetes. 1995.
203.
Elliott J, Jacques RM, Kruger J, Campbell MJ, Amiel SA, Mansell P, et al. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabetic Medicine. 2014;31(7):847–853. [PMC free article: PMC4264891] [PubMed: 24654672]
204.
Ellis D, Coonrod BA, Dorman JS, Kelsey SF, Becker DJ, Avner ED, et al. Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus. American Journal of Kidney Diseases. 1989;13(4):321–328. [PubMed: 2705450]
205.
Ellison JM, Stegmann JM, Colner SL, Michael RH, Sharma MK, Ervin KR, et al. Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites. Diabetes Care. 2002;25(6):961–964. [PubMed: 12032099]
206.
Elwyn GJ, Vaughan NJ, Stott NC. District diabetes registers: more trouble than they're worth? Diabetic Medicine. 1998;15(Suppl. 3):S44–S48. [PubMed: 9829769]
207.
Engelbrecht R, Hildebrand C. DIABCARD a smart card for patients with chronic diseases. Clinical Performance & Quality Health Care. 1997;5(2):67–70. [PubMed: 10167214]
208.
Engelbrecht R, Hildebrand C. Telemedicine and diabetes. Studies in Health Technology and Informatics. 1999;64:142–154. [PubMed: 10747533]
209.
Engelbrecht R, Hildebrand C, Brugues E, de Leiva A, Corcoy R. DIABCARD--an application of a portable medical record for persons with diabetes. Medical Informatics. 1996;21(4):273–282. [PubMed: 9179832]
210.
Engelbrecht R, Hildebrand C, Kuhnel E, Brenner G, Corcoy R, Eberhard G, et al. A chip card for patients with diabetes. Computer Methods and Programs in Biomedicine. 1994;45(1-2):33–35. [PubMed: 7889759]
211.
Ericsson Å, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Journal of Medical Economics. 2013;16(12):1442–1452. [PubMed: 24147661]
212.
ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268(10):1292–1300. [PubMed: 1507375]
213.
ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus Early Treatment Diabetic Retinopathy Study report 14. Personal communication. 2013. [PubMed: 1507375]
214.
Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999;319(7202):83–86. [PMC free article: PMC28155] [PubMed: 10398627]
215.
Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. Clinics in Endocrinology and Metabolism. 1986;15(4):855–888. [PubMed: 3536203]
216.
Faes TJ, Yff GA, DeWeerdt O, Lanting P, Heimans JJ, Bertelsmann FW. Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. Journal of Neurology. 1993;240(3):156–160. [PubMed: 8482988]
217.
Fan H, Pan Q, Zhang P, Liu J, Xu Y, Yang X. Influence of islet function on typing and prognosis of new-onset diabetes after intensive insulin therapy. Medical Science Monitor. 2013;19:787–793. [PMC free article: PMC3787858] [PubMed: 24056309]
218.
Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Di Vincenzo A, Modarelli F, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia. 1994;37(12):1265–1276. [PubMed: 7895957]
219.
Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42(11):1683–1689. [PubMed: 8405713]
220.
Fanelli CG, Pampanelli S, Porcellati F, Rossetti P, Brunetti P, Bolli GB. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Annals of Internal Medicine. 2002;136(137):504–514. [PubMed: 11926785]
221.
Fares JE, Kanaan M, Chaaya M, Azar ST. Fluctuations in glycosylated hemoglobin (HbA1C) as a predictor for the development of diabetic nephropathy in type 1 diabetic patients. International Journal of Diabetes Mellitus. 2010;2(1):10–14.
222.
Faronato P, de Bigontina G. A cost-benefit analysis of two mass screening strategies for albuminuria in diabetic patients. Diabetes, Nutrition and Metabolism - Clinical and Experimental. 1994;7(6):325–329.
223.
Fendrick AM, Javitt JC, Chiang YP. Cost-effectiveness of the screening and treatment of diabetic retinopathy. What are the costs of underutilization? International Journal of Technology Assessment in Health Care. 1992;8(4):694–707. [PubMed: 1464489]
224.
Ferguson SC, Strachan MW, Janes JM, Frier BM. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes/Metabolism Research and Reviews. 2001;17(4):285–291. [PubMed: 11544612]
225.
Ferrier C, Ferrari P, Weidmann P, Keller U, Beretta-Piccoli C, Riesen WF. Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients. Drugs. 1992;44(Suppl.1):74–84. [PubMed: 1283588]
226.
Fialkow PJ, Zavala C, Nielsen R. Thyroid autoimmunity: increased frequency in relatives of insulin-dependent diabetes patients. Annals of Internal Medicine. 1975;83(2):170–176. [PubMed: 1147450]
227.
Fischer U, Salzsieder E, Menzel R, Vogt L, Ropke H, Schmidt R, et al. Primary health care of diabetic patients in a specialized outpatient setting: a DIABCARE-based analysis. Diabetes & Metabolism. 1993;19(1 Pt.2):188–194. [PubMed: 8314425]
228.
Fisher EB, Auslander WF, Munro JF, Arfken, et al. Neigbors for a smoke free North Side: Evaluation of a community organization approach to promoting smoking cessation among African Americans. American Journal of Public Health. 1998;88:1658–1663. [PMC free article: PMC1508568] [PubMed: 9807532]
229.
Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. Journal of Clinical Endocrinology & Metabolism. 1983;57(1):177–180. [PubMed: 6406531]
230.
Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. New England Journal of Medicine. 1977;297(5):238–241. [PubMed: 406561]
231.
Fisher L, Chesla CA, Bartz RJ, Gilliss C, Skaff MA, Sabogal F, et al. The family and type 2 diabetes: a framework for intervention. Diabetes Educator. 1998;24(5):599–607. [PubMed: 9830956]
232.
Fontvieille AM, Rizkalla SW, Penfornis A, Acosta M, Bornet FR, Slama G. The use of low glycaemic index foods improves metabolic control of diabetic patients over five weeks. Diabetic Medicine. 1992;9(5):444–450. [PubMed: 1611832]
233.
Forde R. Review of diabetes structured education. Health Services Executive, Republic of Ireland. 2009. Available from: http://www​.hse.ie/eng​/services/Publications​/topics/Diabetes/diabetesstructureded.pdf.
234.
Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis. 2000;148(1):159–169. [PubMed: 10580182]
235.
Franc S, Dardari D, Boucherie B, Riveline JP, Biedzinski M, Petit C, et al. Real-life application and validation of flexible intensive insulin-therapy algorithms in type 1 diabetes patients. Diabetes & Metabolism. 2009;35(6):463–468. [PubMed: 19914853]
236.
Frank A, Deng S, Huang X, Velidedeoglu E, Bae YS, Liu C, et al. Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Annals of Surgery. 2004;240(4):631–633. [PMC free article: PMC1356465] [PubMed: 15383791]
237.
Frank RN. Aldose reductase inhibition. The chemical key to the control of diabetic retinopathy? Archives of Ophthalmology. 1990;108(9):1229–1231. [PubMed: 2119167]
238.
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. American Journal of Gastroenterology. 2008;103(2):416–423. [PubMed: 18070232]
239.
Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes/Metabolism Research and Reviews. 2008;24(2):87–92. [PubMed: 18088077]
240.
Fritsche A, Stefan N, Haring H, Gerich J, Stumvoll M. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Annals of Internal Medicine. 2001;134(9 Pt 1):729–736. [PubMed: 11329230]
241.
Frokjaer JB, Ejskjaer N, Rask P, Due AS, Gregersen H, Drewes AM, et al. Central neuronal mechanisms of gastric electrical stimulation in diabetic gastroparesis. Scandinavian Journal of Gastroenterology. 2008;43(9):1066–1075. [PubMed: 18609155]
242.
Frykberg RG. Team approach toward lower extremity amputation prevention in diabetes. Journal of the American Podiatric Medical Association. 1997;87(7):305–312. [PubMed: 9241972]
243.
Fukunishi I, Horikawa N, Yamazaki T, Shirasaka K, Kanno K, Akimoto M. Perception and utilization of social support in diabetic control. Diabetes Research and Clinical Practice. 1998;41(3):207–211. [PubMed: 9829351]
244.
Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal. 2005;35(9):536–542. [PubMed: 16105155]
245.
Furnary AP. Rationale for glycemic control in cardiac surgical patients: The portland diabetic project. Insulin. 2006;1(SUPPL. 1):S24–S29.
246.
Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2004;10(Suppl.2):21–33. [PubMed: 15251637]
247.
Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabetic Medicine. 2000;17(3):209–214. [PubMed: 10784225]
248.
Gamba G, Oseguera J, Castrejon M, Gomez-Perez FJ. Bicarbonate therapy in severe diabetic ketoacidosis. A double blind, randomized, placebo controlled trial. Revista De Investigacion Clinica. 1991;43(3):234–238. [PubMed: 1667955]
249.
Game FL, Bartlett WA, Bayly GR, Jones AF. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes, Obesity & Metabolism. 2001;3(4):279–286. [PubMed: 11520308]
250.
Game FL, Jones AF. Coronary heart disease risk assessment in diabetes mellitus - A comparison of PROCAM and Framingham risk assessment functions. Diabetic Medicine. 2001;18(5):355–359. [PubMed: 11472444]
251.
Gan RM, Wong V, Cheung NW, McLean M. Effect of insulin infusion on electrocardiographic findings following acute myocardial infarction: importance of glycaemic control. Diabetic Medicine. 2009;26(2):174–176. [PubMed: 19236622]
252.
Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Annals of Internal Medicine. 2007;146(4):233–243. [PubMed: 17310047]
253.
Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, Williams BA, et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clinic Proceedings. 2005;80(7):862–866. [PubMed: 16007890]
254.
Gandhi K, Hussain SS, Charatsi E, Dornhorst A. Investigating hypoglycaemia awareness in an outpatient Type 1 diabetes clinic. Diabetic Medicine. 2013;30(Suppl.1):148.
255.
Garattini L, Brunetti M, Salvioni F, Barosi M. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. Pharmacoeconomics. 1997;12(1):67–75. [PubMed: 10169388]
256.
Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44–50. [PubMed: 16373894]
257.
Garg SK, Rosenstock J, Ways K. Optimized Basal–bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocrine Practice. 2005;11(1):11–17. [PubMed: 16033730]
258.
Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabetic Medicine. 2008;25(4):501–504. [PubMed: 18387080]
259.
Geddes J, Wright RJ, Zammitt NN, Deary IJ, Frier BM. An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care. 2007;30(7):1868–1870. [PubMed: 17416785]
260.
George JT, Valdovinos AP, Russell I, Dromgoole P, Lomax S, Torgerson DJ, et al. Clinical effectiveness of a brief educational intervention in type 1 diabetes: Results from the BITES (Brief Intervention in Type 1 diabetes, Education for Self-efficacy) trial. Diabetic Medicine. 2008;25(12):1447–1453. [PMC free article: PMC2701554] [PubMed: 19046244]
261.
Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Annals of Neurology. 2010;67(4):534–541. [PMC free article: PMC3057039] [PubMed: 20437589]
262.
Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Current Medical Research and Opinion. 2010;26(6):1519–1530. [PubMed: 20429833]
263.
Gill JS, Williams G, Ghatei MA, Hetreed AH, Mather HM, Bloom SR. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabetes & Metabolism. 1990;16:296–302. [PubMed: 2125013]
264.
Gillespie P, O'Shea E, O'Hara MC, Dinneen SF. Irish DAFNE Study Group. Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial. Trials. 2014;15:227. [PMC free article: PMC4070096] [PubMed: 24927851]
265.
Gimenez M, Lara M, Conget I. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technology and Therapeutics. 2010;12(7):517–521. [PubMed: 20597825]
266.
Gimenez M, Lara M, Jimenez A, Conget I. Glycaemic profile characteristics and frequency of impaired awareness of hypoglycaemia in subjects with T1D and repeated hypoglycaemic events. Acta Diabetologica. 2009;46(4):291–293. [PubMed: 19107319]
267.
Glasgow RE, La Chance PA, Toobert DJ, Brown J, Hampson SE, Riddle MC. Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office. Patient Education and Counseling. 1997;32:175–184. [PubMed: 9423499]
268.
Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17(7):697–703. [PubMed: 7924780]
269.
Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98:2513–2519. [PubMed: 9843456]
270.
Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–783. [PubMed: 12610037]
271.
Golen LW, Ijzerman RG, Huisman MC, Hensbergen JF, Hoogma RP, Drent ML, et al. Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: A randomized controlled crossover trial. Diabetes Care. 2013;36(12):4050–4056. [PMC free article: PMC3836102] [PubMed: 24130356]
272.
Golightly LK, Jones MA, Hamamura DH, Stolpman NM, McDermott MT. Management of diabetes mellitus in hospitalized patients: Efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy. 2006;26(10):1421–1432. [PubMed: 16999652]
273.
Gomez JM, Maravall FJ, Guma A, Abos R, Soler J, Fernandez-Castaner M. Thyroid volume as measured by ultrasonography in patients With type 1 diabetes mellitus without thyroid dysfunction. Hormone and Metabolic Research, Hormon Und Stoffwechselforschung, Hormones Et Métabolisme. 2003;35(8):486–491. [PubMed: 12953166]
274.
Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain. 1985;23(4):395–400. [PubMed: 3911140]
275.
Gonder-Frederick LA, Julian DM, Cox DJ, Clarke WL, Carter WR. Self-measurement of blood glucose. Accuracy of self-reported data and adherence to recommended regimen. Diabetes Care. 1988;11(7):579–585. [PubMed: 3203575]
276.
Gordon D, Semple CG, Paterson KR. Do different frequencies of self-monitoring of blood glucose influence control in type 1 diabetic patients? Diabetic Medicine. 1991;8(7):679–682. [PubMed: 1833122]
277.
Gorman C, Looker J, Fisk T, Oelke W, Erickson D, Smith S, et al. A clinically useful diabetes electronic medical record: lessons from the past; pointers toward the future. European Journal of Endocrinology. 1996;134(1):31–42. [PubMed: 8590952]
278.
Gossain VV, Gunaga KP, Carella MJ, Edminster RR, Bowman KA, Rovner DR. Utility of micral test strips in screening for microalbuminuria. Archives of Pathology & Laboratory Medicine. 1996;120(11):1015–1018. [PubMed: 12049101]
279.
Grabert M, Schweiggert F, Holl RW. A framework for diabetes documentation and quality management in Germany: 10 years of experience with DPV. Computer Methods and Programs in Biomedicine. 2002;69(2):115–121. [PubMed: 12100791]
280.
Grant L, Lawton J, Hopkins D, Elliott J, Lucas S, Clark M, et al. Type 1 diabetes structured education: What are the core self-management behaviours? Diabetic Medicine. 2013;30(6):724–730. [PubMed: 23461799]
281.
Grieve R, Beech R, Vincent J, Mazurkiewicz J. Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technology Assessment. 1999;3(15):1–74. [PubMed: 10632625]
282.
Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics. 2007;25(3):253–266. [PubMed: 17335310]
283.
Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technology and Therapeutics. 2003;5(3):365–369. [PubMed: 12828818]
284.
Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DR. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care. 2001;24(1):45–50. [PubMed: 11194239]
285.
Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated? Circulation. 2000;102(7):722–727. [PubMed: 10942738]
286.
Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nature Reviews Endocrinology. 2013;9(9):555–562. [PubMed: 23897173]
287.
Guerci B, Meyer L, Sommer S, George JL, Ziegler O, Drouin P, et al. Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetic patients. Diabetes & Metabolism. 1999;25(5):412–418. [PubMed: 10592864]
288.
Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. Journal of Medical Economics. 2011;14(2):207–216. [PubMed: 21361858]
289.
Hamaguchi K, Kimura A, Kusuda Y, Yamashita T, Yasunami M, Takahasi M, et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Research and Clinical Practice. 2004;66(2):163–171. [PubMed: 15533584]
290.
Hampe CS, Maitland ME, Gilliam LK, Phan THT, Sweet IR, Radtke JR, et al. High titers of autoantibodies to glutamate decarboxylase in type 1 diabetes patients: epitope analysis and inhibition of enzyme activity. Endocrine Practice. 2013;19(4):663–668. [PMC free article: PMC4037149] [PubMed: 23512385]
291.
Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care. 2010;33(8):1903–1904. [PMC free article: PMC2909083] [PubMed: 20519665]
292.
Hanestad BR, Albrektsen G. The effects of participation in a support group on self assessed quality of life in people with insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice. 1993;19(2):163–173. [PubMed: 8472631]
293.
Hannon MJ, Dinneen S, Yousif O, Thompson CJ, Quigley EMM, O'Halloran DJ. Gastric pacing for diabetic gastroparesis--does it work? Irish Medical Journal. 2011;104(5):135–137. [PubMed: 21736087]
294.
Hansen HP, Gaede PH, Jensen BR, Parving H-H. Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care. 2000;23(12):1742–1745. [PubMed: 11128344]
295.
Hanson CL, Henggeler SW, Burghen GA. Social competence and parental support as mediators of the link between stress and metabolic control in adolescents with insulin-dependent diabetes mellitus. Journal of Consulting and Clinical Psychology. 1987;55:529–533. [PubMed: 3624608]
296.
Hanukoglu A, Mizrachi A, Dalal I, Admoni O, Rakover Y, Bistritzer Z, et al. Extrapancreatic autoimmune manifestations in type 1 diabetes patients and their first-degree relatives: A multicenter study. Diabetes Care. 2003;26(4):1235–1240. [PubMed: 12663603]
297.
Harris MF, Priddin D, Ruscoe W, Infante FA, O'Toole BI. Quality of care provided by general practitioners using or not using Division-based diabetes registers. Medical Journal of Australia. 2002;177(5):250–252. [PubMed: 12197819]
298.
Harris S, Ng R, Syed H, Hillson R. Near patient blood ketone measurements and their utility in predicting diabetic ketoacidosis. Diabetic Medicine. 2005;22(2):221–224. [PubMed: 15660743]
299.
Hartemann-Heurtier A, Sultan S, Sachon C, Bosquet F, Grimaldi A. How type 1 diabetic patients with good or poor glycemic control cope with diabetes-related stress. Diabetes & Metabolism. 2001;27(5 Pt 1):553–559. [PubMed: 11694854]
300.
Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabetic Medicine : a Journal of the British Diabetic Association. 2008;25(2):138–146. [PubMed: 18290855]
301.
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care. 2013;36(4):908–913. [PMC free article: PMC3609504] [PubMed: 23248199]
302.
Health and Social Care Information Centre. Prescription cost analysis - England, 2012 [NS] 2013. [6 January 2014].
303.
Health Technology Board for Scotland (HTBS). Organization of services for diabetic retinopathy screening (project). Health Technology Board for Scotland (HTBS); 2002. Available from: http://www​.htbs.org.uk.
304.
Hearnshaw H, Hopkins J, Wild A, MacKinnon M, Gadsby R, Dale J. Mandatory, multidisciplinary education in diabetes care. Can it meet the needs of primary care organisations? Practical Diabetes International. 2001;18(8):274–280.
305.
Heinemann L, Pettis RJ, Hirsch LJ, Nosek L, Kapitza C, Sutter DE, et al. Microneedle-based intradermal injection of lispro or human regular insulin accelerates insulin uptake and reduces post-prandial glycaemia. Diabetologia. 2009;52(S1):S378.
306.
Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, et al. Insulin degludec: Less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia. 2010;53(Suppl.1):S387.
307.
Heise T, Nosek L, Rã¸Nn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614–1620. [PubMed: 15161770]
308.
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal–bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–1497. [PubMed: 22521071]
309.
Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal–bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clinical Therapeutics. 2009;31(10):2086–2097. [PubMed: 19922879]
310.
Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care. 1999;22(10):1607–1611. [PubMed: 10526722]
311.
Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine. 2004;21(7):769–775. [PubMed: 15209772]
312.
Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40(2):223–226. [PubMed: 1991573]
313.
Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabetic Medicine. 2003;20(12):1016–1021. [PubMed: 14632703]
314.
Hendrieckx C, Halliday JA, Bowden JP, Colman PG, Cohen N, Jenkins A, et al. Severe hypoglycaemia and its association with psychological well-being in Australian adults with type 1 diabetes attending specialist tertiary clinics. Diabetes Research and Clinical Practice. 2014;103(3):430–436. [PubMed: 24513121]
315.
Hendry BM, Viberti GC, Hummel S, Bagust A, Piercy J. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM: Monthly Journal of the Association of Physicians. 1997;90(4):277–282. [PubMed: 9307762]
316.
Hentinen M, Kyngas H. Diabetic adolescents' compliance with health regimens and associated factors. International Journal of Nursing Studies. 1996;33:325–337. [PubMed: 8736477]
317.
Herman WH, Dasbach EJ, Songer TJ, Eastman RC. The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinology and Metabolism Clinics of North America. 1997;26(3):679–695. [PubMed: 9314022]
318.
Hermanns N, Kulzer B, Kubiak T, Krichbaum M, Haak T. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2007;23(7):528–538. [PubMed: 17245692]
319.
Hermanns N, Kulzer B, Ehrmann D, Bergis-Jurgan N, Haak T. The effect of a diabetes education programme (PRIMAS) for people with type 1 diabetes: results of a randomized trial. Diabetes Research and Clinical Practice. 2013;102(3):149–157. [PubMed: 24210673]
320.
Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal–bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47(4):622–629. [PubMed: 15298338]
321.
Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: A randomized open crossover trial in type 1 diabetic subjects on basal–bolus therapy. Diabetes Care. 2001;24(2):296–301. [PubMed: 11213882]
322.
Hernandez CA, Hume MR, Rodger NW. Evaluation of a self-awareness intervention for adults with type 1 diabetes and hypoglycemia unawareness. Canadian Journal of Nursing Research. 2008;40(3):38–56. [PubMed: 18947091]
323.
Herpertz S, Wagener R, Albus C, Kocnar M, Wagner R, Best F, et al. Diabetes mellitus and eating disorders: a multicenter study on the comorbidity of the two diseases. Journal of Psychosomatic Research. 1998;44(3-4):503–515. [PubMed: 9587892]
324.
Herz M, Arora V, Sun B, Ferguson SC, Bolli GB, Frier BM. Basal–bolus insulin therapy in Type 1 diabetes: Comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. Diabetic Medicine. 2002;19(11):917–923. [PubMed: 12421428]
325.
Hietala K, Waden J, Forsblom C, Harjutsalo V, Kyto J, Summanen P, et al. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia. 2013;56(4):737–745. [PubMed: 23314044]
326.
Hillman M, Torn C, Landin-Olsson M. DISS study group. The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset. Clinical and Experimental Immunology. 2009;157(2):255–260. [PMC free article: PMC2730851] [PubMed: 19604265]
327.
Hillman N, Herranz L, Grande C, Vaquero PM, Pallardo LF. What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes? Diabetic Medicine. 2004;21(5):468–470. [PubMed: 15089792]
328.
Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technology and Therapeutics. 2008;10(5):377–383. [PubMed: 18715214]
329.
Hirsch IB, Brownlee M. Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications. JAMA : the Journal of the American Medical Association. 2010;303(22):2291–2292. [PubMed: 20530784]
330.
Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal–bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35(11):2174–2181. [PMC free article: PMC3476910] [PubMed: 22933438]
331.
Hirsch LJ, Gibney MA, Albanese J, Qu S, Kassler-Taub K, Klaff LJ, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2010;26(6):1531–1541. [PubMed: 20429832]
332.
Hirsch LJ, Gibney MA, Li L, Berube J. Glycemic control, reported pain and leakage with a 4 mm × 32 G pen needle in obese and non-obese adults with diabetes: a post hoc analysis. Current Medical Research and Opinion. 2012;28(8):1305–1311. [PubMed: 22762347]
333.
Hiscock J, Ligard R, Snape Listening to Diabetes Service Users: Qualitative findings for the diabetes National Service Framework. Department of Health; 2003. Available from: Department of Health website www​.doh.gov.uk.
334.
Hislop AL, Fegan PG, Schlaeppi MJ, Duck M, Yeap BB. Prevalence and associations of psychological distress in young adults with Type 1 diabetes. Diabetic Medicine. 2008;25(1):91–96. [PubMed: 18199136]
335.
Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Classification of hypoglycemia awareness in people with type 1 diabetes in clinical practice. Journal of Diabetes and Its Complications. 2010;24(6):392–397. [PubMed: 19796968]
336.
Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH, et al. Reduced frequency of severe hypoglycemia and coma well-controlled IDDM patients treated with insulin lispro. Diabetes Care. 1997;20(12):1827–1832. [PubMed: 9405901]
337.
Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27(5):1081–1087. [PubMed: 15111525]
338.
Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obesity and Metabolism. 2012;14(9):780–788. [PubMed: 22321739]
339.
Home PD, Coles J, Goldacre M, Mason A, Wilkinson E. A report of a working group to the Department of Health. Oxford: National centre for health outcomes development; 1999. Health outcome indicators: Diabetes.
340.
Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Research and Clinical Practice. 2006;71(2):131–139. [PubMed: 16054266]
341.
Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care. 1998;21(11):1904–1909. [PubMed: 9802741]
342.
Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabetic Medicine. 2000;17(11):762–770. [PubMed: 11131100]
343.
Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, et al. Improved health status with insulin degludec compared with insulin glargine in people with Type1 diabetes. Diabetic Medicine. 2012;29(6):716–720. [PMC free article: PMC3397676] [PubMed: 22150786]
344.
Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2005;21(6):545–553. [PubMed: 16021649]
345.
Hommel E, Andersen P, Gall M-A, Nielsen F, Jensen B, Rossing P, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35(5):447–451. [PubMed: 1521727]
346.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, et al. Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine. 2013;30(11):1342–1348. [PMC free article: PMC4154136] [PubMed: 23659458]
347.
Hopkins D, Lawrence I, Mansell P, Thompson G, Amiel S, Campbell M, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012;35(8):1638–1642. [PMC free article: PMC3402270] [PubMed: 22619082]
348.
Hopkinson HE, Jacques RM, Gardner KJ, Amiel SA, Mansell P. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management. Diabetic Medicine : a Journal of the British Diabetic Association. 2015 [PMC free article: PMC4745019] [PubMed: 25982032]
349.
Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJ. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Digestive Diseases and Sciences. 1985;30(1):1–9. [PubMed: 3965269]
350.
Horsley W. Gastroelectrical stimulation for gastroparesis. North East Treatment Advisory Group; 2010. Available from: http://www​.netag.nhs​.uk/files/appraisal-reports​/Gastroelectrical​%20stimulation%20-​%20NETAG%20appraisal​%20report%20-Apr10.pdf.
351.
Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care. 2003;26(2):452–457. [PubMed: 12547879]
352.
Howitt AJ, Cheales NA. Diabetes registers: a grassroots approach. BMJ. 1993;307(6911):1046–1048. [PMC free article: PMC1679253] [PubMed: 8251780]
353.
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010;33(6):1269–1274. [PMC free article: PMC2875436] [PubMed: 20332354]
354.
Huang G, Xiang Y, Pan L, Li X, Luo S, Zhou Z. Zinc transporter 8 autoantibody (ZnT8A) could help differentiate latent autoimmune diabetes in adults (LADA) from phenotypic type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews. 2013;29(5):363–368. [PubMed: 23390067]
355.
Huang Z, Chen Y, Li F, Li Y. Clinical heterogeneity of type 1 diabetes mellitus at onset. Diabetologia. 2010;53(Suppl.1):S396.
356.
Husband DJ, Thai AC, Alberti KG. Management of diabetes during surgery with glucose-insulin-potassium infusion. Diabetic Medicine. 1986;3(1):69–74. [PubMed: 2951140]
357.
Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy - A systematic review. Diabetic Medicine. 2000;17(7):495–506. [PubMed: 10972578]
358.
Hutchinson MS, Joakimsen RM, Njolstad I, Schirmer H, Figenschau Y, Jorde R. Glycated hemoglobin in diagnosis of diabetes mellitus and pre-diabetes; validation by oral glucose tolerance test. The Tromso OGTT Study. Journal of Endocrinological Investigation. 2012;35(9):835–840. [PubMed: 22186659]
359.
Hwangbo Y, Kim JT, Kim EK, Khang AR, Oh TJ, Jang HC, et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic Acid decarboxylase antibody. Diabetes & Metabolism. 2012;36(2):136–143. [PMC free article: PMC3335895] [PubMed: 22540050]
360.
Ignaut DA, Fu H. Comparison of insulin diluent leakage postinjection using two different needle lengths and injection volumes in obese patients with type 1 or type 2 diabetes mellitus. Journal of Diabetes Science and Technology. 2012;6(2):389–393. [PMC free article: PMC3380784] [PubMed: 22538152]
361.
International Diabetes Foundation. A guide to Type 1 (insulin dependant) Diabetes Mellitus. Brussels: International Diabetes Federation; 1998.
362.
Ishii N, Nagao K, Fujikawa K, Tachibana T, Iwamoto Y, Kamidono S. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. International Journal of Urology : Official Journal of the Japanese Urological Association. 2006;13(8):1066–1072. [PubMed: 16903931]
363.
Iwamoto Y, Clauson P, Nishida T, Kaku K. Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial. Journal of Diabetes Investigation. 2013;4(1):62–68. [PMC free article: PMC4019289] [PubMed: 24843632]
364.
Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic and Clinical Pharmacology and Toxicology. 2009;105(3):145–149. [PubMed: 19496776]
365.
Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME. DCCT/EDIC Research Group. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care. 2013;36(10):3131–3138. [PMC free article: PMC3781542] [PubMed: 23835693]
366.
Janssen MM, Snoek FJ, Heine RJ. Assessing impaired hypoglycemia awareness in type 1 diabetes: agreement of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia. Diabetes Care. 2000;23(4):529–532. [PubMed: 10857947]
367.
Janssen MM, Snoek FJ, Masurel N, Hoogma RP, Deville WL, Popp-Snijders C, et al. Optimized basal–bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction. Diabetes Care. 2000;23(5):629–633. [PubMed: 10834421]
368.
Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. New England Journal of Medicine. 1990;322(15):1028–1031. [PubMed: 2320062]
369.
Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Annals of Internal Medicine. 1996;124(1 Pt 2):164–169. [PubMed: 8554212]
370.
Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology. 1991;98(10):1565–1573. [PubMed: 1961646]
371.
Javitt JC, Canner JK, Frank RG, Steinwachs DM, Sommer A. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology. 1990;97(4):483–494. [PubMed: 2109299]
372.
Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology. 1989;96(2):255–264. [PubMed: 2495499]
373.
Javor KA, Kotsanos JG, McDonald RC, Baron AD, Kesterson JG, Tierney WM. Diabetic ketoacidosis charges relative to medical charges of adult patients with type I diabetes. Diabetes Care. 1997;20(3):349–354. [PubMed: 9051386]
374.
Jin P, Huang G, Lin J, Yang L, Xiang B, Zhou W, et al. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults. Clinical Endocrinology. 2011;74(5):587–592. [PubMed: 21470281]
375.
Johnston JH, Cook AT. Treatment of diabetic ketoacidosis with small doses of insulin. Journal of the Royal Army Medical Corps. 1977;123(1):32–36.
376.
Johnston SD, Ritchie C, Robinson J. Application of red cell distribution width to screening for coeliac disease in insulin-dependent diabetes mellitus. Irish Journal of Medical Science. 1999;168(3):167–170. [PubMed: 10540781]
377.
Joint Diabetes UK and Department of Health patient education working group. Structured patient education in diabetes: report from the patient education working group. Department of Health; Diabetes UK; 2005. Available from: http://www​.diabetes.org​.uk/Documents/Reports​/StructuredPatientEd.pdf.
378.
Joint Formulary Committee. British National Formulary (BNF). 64th edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2012. Available from: http://www​.bnf.org.uk.
379.
Joint Formulary Committee. British National Formulary (BNF). 67th edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2014. Available from: http://www​.bnf.org.uk.
380.
Jones AF, Walker J, Jewkes C, Game FL, Bartlett WA, Marshall T, et al. Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart. 2001;85(1):37–43. [PMC free article: PMC1729574] [PubMed: 11119458]
381.
Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia. 1999;42(11):1293–1301. [PubMed: 10550412]
382.
Junik R, Kozinski M, Debska-Kozinska K. Thyroid ultrasound in diabetic patients without overt thyroid disease. Acta Radiologica. 2006;47(7):687–691. [PubMed: 16950706]
383.
Kamenov ZA. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. Journal of Sexual Medicine. 2011;8(3):851–864. [PubMed: 21143421]
384.
Kanc K, Kastrin A, Kastrin M, Gonder-Frederick LA. Fear of hypoglycaemia - How to identify patients at risk in a routine clinical practice? Diabetologia. 2010;53(Suppl.1):S237–S238.
385.
Kanters SDJM, Banga J-D, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: A meta-analysis. Vascular Medicine. 1999;4(2):67–75. [PubMed: 10406452]
386.
Kaplan RM, Hartwell SL. Differential effects of social support and social network on physiological and social outcomes in men and women with type II diabetes. Health Psychology. 1987;6:387–398. [PubMed: 3678167]
387.
Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabetic Medicine. 2005;22(10):1444–1445. [PubMed: 16176210]
388.
Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RBJ, Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. American Journal of Medicine. 2001;111(1):1–9. [PubMed: 11448654]
389.
Kawamori R, Kadowaki T, Ishii H, Iwasaki M, Iwamoto Y. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 2009;11(9):891–899. [PubMed: 19614947]
390.
Kelley DE. Sugars and starch in the nutritional management of diabetes mellitus. American Journal of Clinical Nutrition. 2003;78(4):858S–864S. [PubMed: 14522750]
391.
Kelly W, Bilous R, Murray G. A comprehensive register for diabetic outpatients: experience with desktop computing from 1987-1996. Computer Methods and Programs in Biomedicine. 1998;56(2):205–210. [PubMed: 9700434]
392.
Kendall DM, Rooney DP, Smets YF, Salazar BL, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes. 1997;46(2):249–257. [PubMed: 9000702]
393.
Khachadurian AK, Davidson JA, Braunstein S, Redmond G, Greenfield M, Lauritano AA, et al. Comparison of fixed-ratio versus variable-ratio regular and NPH semisynthetic human insulin in insulin-requiring diabetic patients. Clinical Therapeutics. 1989;11(4):485–494. [PubMed: 2673516]
394.
Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. Diabetic Medicine. 2006;23(10):1079–1084. [PubMed: 16978371]
395.
Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ. 1995;311(7020):1595–1599. [PMC free article: PMC2551496] [PubMed: 8555801]
396.
Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011;34(7):1463–1468. [PMC free article: PMC3120168] [PubMed: 21593296]
397.
Kilbride L, Charlton J, Aitken G, Hill GW, Davison RCR, McKnight JA. Managing blood glucose during and after exercise in Type 1 diabetes: reproducibility of glucose response and a trial of a structured algorithm adjusting insulin and carbohydrate intake. Journal of Clinical Nursing. 2011;20(23-24):3423–3429. [PubMed: 21884557]
398.
Kim CS, Song MK, Park JS, Cho MH, Kim HJ, Nam JS, et al. The clinical and immunogenetic characteristics of adult-onset type 1 diabetes mellitus in Korea. Acta Diabetologica. 2007;44(2):45–54. [PubMed: 17530466]
399.
Kirsten C, Manning P. Otago Diabetes Team. Establishing a regional diabetes register and a description of the registered population after one year. New Zealand Medical Journal. 2002;115(1160):U146. [PubMed: 12362203]
400.
Klein BE, Klein R, Moss SE. Self-rated health and diabetes of long duration. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1998;21(2):236–240. [PubMed: 9539988]
401.
Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18(2):258–268. [PubMed: 7729308]
402.
Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Annals of Internal Medicine. 1996;124(1 Pt 2):90–96. [PubMed: 8554220]
403.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801–1815. [PubMed: 9787347]
404.
Klein R, Moss SE, Klein BE. Change in glycemia in a four-year interval in younger-onset insulin-dependent diabetes. Annals of Epidemiology. 1992;2(3):283–294. [PubMed: 1342279]
405.
Kleschen MZ, Holbrook J, Rothbaum AK, Stringer RA, McInerney MJ, Helgerson SD. Improving the pneumococcal immunization rate for patients with diabetes in a managed care population: a simple intervention with a rapid effect. Joint Commission Journal on Quality Improvement. 2000;26(9):538–546. [PubMed: 10983294]
406.
Klupa T, Benbenek-Klupa T, Malecki M, Szalecki M, Sieradzki J. Clinical usefulness of a bolus calculator in maintaining normoglycaemia in active professional patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. Journal of International Medical Research. 2008;36(5):1112–1116. [PubMed: 18831908]
407.
Knight BG, Lutzky SM, Macofsky-Urban A meta-analytic review of interventions for caregiver distress: recommendations for future research. Gerontologist. 1993;33(2):240–248. [PubMed: 8468017]
408.
Koblik T, Sieradzki J, Friedlein J, Legutko J. First polish multidisciplinary diabetic foot team: Results of the first three years of operation - The Cracow study. Diabetologia Polska. 1999;6(4):233–238.
409.
Kolendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabetic Medicine. 2006;23(7):729–735. [PubMed: 16842476]
410.
Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996;39(4):492–499. [PubMed: 8778001]
411.
Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41(5):577–583. [PubMed: 9628276]
412.
Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care. 1997;20(3):355–361. [PubMed: 9051387]
413.
Kopelman PG, Michell JC, Sanderson AJ. DIAMOND: a computerized system for the management and evaluation of district-wide diabetes care. Diabetic Medicine. 1995;12(1):83–87. [PubMed: 7712711]
414.
Koproski J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care. 1997;20(10):1553–1555. [PubMed: 9314634]
415.
Korhonen T, Huttunen JK, Aro A, Hentinen M, Ihalainen O, Majander H, et al. A controlled trial on the effects of patient education in the treatment of insulin-dependent diabetes. Diabetes Care. 1983;6(3):256–261. [PubMed: 6347578]
416.
Kouri TT, Viikari JS, Mattila KS, Irjala KM. Microalbuminuria. Invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients. Diabetes Care. 1991;14(7):591–593. [PubMed: 1914800]
417.
Kouris I, Mougiakakou S, Scarnato L, Iliopoulou D, Diem P, Vazeou A, et al. Mobile phone technologies and advanced data analysis towards the enhancement of diabetes self-management. International Journal of Electronic Healthcare. 2010;5(4):386–402. [PubMed: 21041177]
418.
Kovatchev BP, Cox DJ, Straume M, Farhy LS. Association of self-monitoring blood glucose profiles with glycosylated hemoglobin in patients with insulin-dependent diabetes. Methods in Enzymology. 2000;321:410–417. [PubMed: 10909069]
419.
Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technology and Therapeutics. 2008;10(5):391–396. [PMC free article: PMC2979337] [PubMed: 18715216]
420.
Kowalske KJ, Agre JC. Neuromuscular rehabilitation and electrodiagnosis. 3. Generalized peripheral neuropathy. Archives of Physical Medicine and Rehabilitation. 2000;81(3 Suppl 1):S20–S26. [PubMed: 10721757]
421.
Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BH. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technology and Therapeutics. 2011;13(7):737–741. [PMC free article: PMC3118929] [PubMed: 21476936]
422.
Kruger J, Brennan A, Thokala P, Basarir H, Jacques R, Elliott J, et al. The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: An update using the Sheffield Type 1 Diabetes Policy Model. Diabetic Medicine. 2013;30(10):1236–1244. [PubMed: 23815547]
423.
Kucera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M. Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clinical and Experimental Immunology. 2003;133(1):139–143. [PMC free article: PMC1808742] [PubMed: 12823288]
424.
Kullberg CE, Finnstrom K, Arnqvist HJ. Severity of background retinopathy in type 1 diabetes increases with the level of long-term glycated haemoglobin. Acta Opthalmologica. 1994;72(2):181–188. [PubMed: 8079623]
425.
Laadhar L, Zitouni M, Kallel-Sellami M, Bouguerra R, Chaabouni H, Makni S. Spectrum of autoantibodies in Tunisian adult type 1 diabetes mellitus. Annals of the New York Academy of Sciences. 2007;1107:356–362. [PubMed: 17804563]
426.
Laaksonen DE, Atalay M, Niskanen LK, Mustonen J, Sen CK, Lakka TA, et al. Aerobic exercise and the lipid profile in type 1 diabetic men: a randomized controlled trial. Medicine & Science in Sports & Exercise. 2000;32(9):1541–1548. [PubMed: 10994902]
427.
Labrecque MS, Peak T. Long term effectiveness of a group program for caregivers of frail elderly veterans. American Journal of Orthopsychiatry. 1992;62(4):575–588. [PubMed: 1443066]
428.
Lachin JM, Orchard TJ, Nathan DM. DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):39–43. [PMC free article: PMC3868002] [PubMed: 24356596]
429.
Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27(10):2341–2347. [PubMed: 15451898]
430.
Laffel LMB, Wentzell K, Loughlin C, Tovar A, Moltz K, Brink S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: A randomized clinical trial. Diabetic Medicine. 2006;23(3):278–284. [PubMed: 16492211]
431.
Lafrance L, Rabasa-Lhoret R, Poisson D, Ducros F, Chiasson JL. Effects of different glycaemic index foods and dietary fibre intake on glycaemic control in type 1 diabetic patients on intensive insulin therapy. Diabetic Medicine. 1998;15(11):972–978. [PubMed: 9827853]
432.
Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care. 1999;22(3):468–477. [PubMed: 10097931]
433.
Langendam M, Luijf YM, Hooft L, DeVries JH, Mudde AH, Scholten Rob JPM. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews. 2012;(Issue 1) CD008101. [PMC free article: PMC6486112] [PubMed: 22258980] [CrossRef]
434.
Larsen ML, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1990;323(15):1021–1025. [PubMed: 2215560]
435.
Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabetic Medicine. 1995;12(9):770–776. [PubMed: 8542736]
436.
Laurenzi A, Bolla AM, Panigoni G, Doria V, Uccellatore A, Peretti E, et al. Effects of carbohydrate counting on glucose control and quality of life over 24 weeks in adult patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized, prospective clinical trial (GIOCAR). Diabetes Care. 2011;34(4):823–827. [PMC free article: PMC3064035] [PubMed: 21378215]
437.
Lawrenson R, Williams J. Antidepressant use in people with diabetes. Diabetes Primary Care. 2001;3(3):70–74.
438.
Lawton J, Rankin D, Cooke D, Elliott J, Amiel S, Heller S. Patients' experiences of adjusting insulin doses when implementing flexible intensive insulin therapy: a longitudinal, qualitative investigation. Diabetes Research and Clinical Practice. 2012;98(2):236–242. [PubMed: 23084281]
439.
Lawton J, Rankin D, Elliott J, Heller SR, Rogers HA, de ZN, et al. Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study. Diabetes Care. 2014;37(1):109–115. [PubMed: 23990515]
440.
Le Floch JP, Charles MA, Philippon C, Perlemuter L. Cost-effectiveness of screening for microalbuminuria using immunochemical dipstick tests or laboratory assays in diabetic patients. Diabetic Medicine. 1994;11(4):349–356. [PubMed: 8088106]
441.
Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal–bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care. 2009;32(1):32–37. [PMC free article: PMC2606825] [PubMed: 18945928]
442.
Le Floch JP, Marre M, Rodier M, Passa P. Interest of Clinitek Microalbumin in screening for microalbuminuria: results of a multicentre study in 302 diabetic patients. Diabetes & Metabolism. 2001;27(1):36–39. [PubMed: 11240444]
443.
Lecaire TJ, Palta M, Klein R, Klein BEK, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 2013;36(3):631–637. [PMC free article: PMC3579344] [PubMed: 23193204]
444.
Lee SA, Lee WJ, Kim EH, Yu JH, Jung CH, Koh EH, et al. Progression to insulin deficiency in Korean patients with Type 2 diabetes mellitus positive for anti-GAD antibody. Diabetic Medicine. 2011;28(3):319–324. [PubMed: 21309840]
445.
Leelarathna L, Little SA, Walkinshaw E, Tan HK, Lubina-Solomon A, Kumareswaran K, et al. Restoration of self-awareness of hypoglycemia in adults with long-standing type 1 diabetes: hyperinsulinemic-hypoglycemic clamp substudy results from the HypoCOMPaSS trial. Diabetes Care. 2013;36(12):4063–4070. [PMC free article: PMC3836150] [PubMed: 24130355]
446.
Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, et al. Insulin detemir used in basal–bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obesity and Metabolism. 2005;7(1):73–82. [PubMed: 15642078]
447.
Lehmann R, Kaplan V, Bingisser R, Bloch KE, Spinas GA. Impact of physical activity on cardiovascular risk factors in IDDM. Diabetes Care. 1997;20(10):1603–1611. [PubMed: 9314643]
448.
Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19(4):1014–1019. [PubMed: 10195930]
449.
Leitao CB, Tharavanij T, Cure P, Pileggi A, Baidal DA, Ricordi C, et al. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care. 2008;31(11):2113–2115. [PMC free article: PMC2571057] [PubMed: 18697903]
450.
Lennon GM, Taylor KG, Debney L, Bailey CJ. Knowledge, attitudes, technical competence, and blood glucose control of Type 1 diabetic patients during and after an education programme. Diabetic Medicine. 1990;7(9):825–832. [PubMed: 2148137]
451.
Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Vincenzo AD, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142–2148. [PubMed: 11118018]
452.
Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003;26(1):1–8. [PubMed: 12502651]
453.
Levetan CS, Salas JR, Wilets IF, Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. American Journal of Medicine. 1995;99(1):22–28. [PubMed: 7598138]
454.
Levitt Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatric Diabetes. 2007;8(2):53–59. [PubMed: 17448127]
455.
Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. Diabetes Care. 1996;19(7):751–754. [PubMed: 8799632]
456.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine. 1993;329(20):1456–1462. [PubMed: 8413456]
457.
Lewis JB. Microalbuminuria: accuracy or economics. American Journal of Kidney Diseases. 1998;32(3):524–528. [PubMed: 9740175]
458.
Ligtenberg PC, Blans M, Hoekstra JB, van dT I, Erkelens DW. No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study. Netherlands Journal of Medicine. 1999;55(2):59–63. [PubMed: 10474273]
459.
Lin SF, Lin JD, Huang YY. Diabetic ketoacidosis: comparisons of patient characteristics, clinical presentations and outcomes today and 20 years ago. Chang Gung Medical Journal. 2005;28(1):24–30. [PubMed: 15804145]
460.
Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140–146. [PubMed: 21705065]
461.
Lindholm E, Hallengren B, Agardh CD. Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases. Diabetes/Metabolism Research and Reviews. 2004;20(2):158–164. [PubMed: 15037992]
462.
Little SA, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, Chadwick TJ, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 ✕ 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care. 2014;37(8):2114–2122. [PubMed: 24854041]
463.
Liu D, McManus RM, Ryan EA. Improved counter-regulatory hormonal and symptomatic responses to hypoglycemia in patients with insulin-dependent diabetes mellitus after 3 months of less strict glycemic control. Clinical and Investigative Medicine. 1996;19(2):71–82. [PubMed: 8697673]
464.
Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Medicine. 2012;9(10):e1001321. [PMC free article: PMC3462745] [PubMed: 23055834]
465.
Lloyd CE, Wing RR, Orchard TJ, Becker DJ. Psychosocial correlates of glycemic control: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. Diabetes Research and Clinical Practice. 1993;21(2-3):187–195. [PubMed: 8269821]
466.
Loveman E, Royle P, Waugh N. Specialist nurses in diabetes mellitus. Cochrane Database of Systematic Reviews. 2003;(2) CD003286. [PMC free article: PMC8407322] [PubMed: 12804458]
467.
Lu H, Hu F, Zeng Y, Zou L, Luo S, Sun Y, et al. Ketosis onset type 2 diabetes had better islet beta-cell function and more serious insulin resistance. Journal of Diabetes Research. 2014;2014:510643. [PMC free article: PMC4009153] [PubMed: 24829925]
468.
Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PloS One. 2008;3(10):e3363. [PMC free article: PMC2566605] [PubMed: 18852875]
469.
Lupi I, Raffaelli V, Di CG, Caturegli P, Manetti L, Ciccarone AM, et al. Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders. Journal of Endocrinological Investigation. 2013;36(2):127–131. [PubMed: 23481612]
470.
Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23(7):934–942. [PubMed: 10895843]
471.
Lustman PJ, Clouse RE, Ciechanowski PS, Hirsch IB, Freedland KE. Depression-related hyperglycemia in type 1 diabetes: a mediational approach. Psychosomatic Medicine. 2005;67(2):195–199. [PubMed: 15784783]
472.
Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23(5):618–623. [PubMed: 10834419]
473.
Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. Diabetes Care. 1995;18(8):1133–1139. [PubMed: 7587848]
474.
Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosomatic Medicine. 1997;59(3):241–250. [PubMed: 9178335]
475.
Maberley D, Walker H, Koushik A, Cruess A. Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. Canadian Medical Association Journal. 2003;168(2):160–164. [PMC free article: PMC140424] [PubMed: 12538543]
476.
MacIsaac RJ, Lee LY, McNeil KJ, Tsalamandris C, Jerums G. Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Internal Medicine Journal. 2002;32(8):379–385. [PubMed: 12162394]
477.
Mahadeb YP, Gruson D, Buysschaert M, Hermans MP. What are the characteristics of phenotypic type 2 diabetic patients with low-titer GAD65 antibodies? Acta Diabetologica. 2014;51(1):103–111. [PubMed: 24193809]
478.
Maioli M, Pes GM, Delitala G, Puddu L, Falorni A, Tolu F, et al. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. European Journal of Endocrinology. 2010;163(4):541–549. [PubMed: 20603341]
479.
Mallamaci F, Zuccala A, Zoccali C, Testa A, Gaggi R, Spoto B, et al. The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis. American Journal of Hypertension. 2000;13(4 I):433–437. [PubMed: 10821348]
480.
Maran A, Lomas J, Macdonald IA, Amiel SA. Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM. Diabetologia. 1995;38(12):1412–1418. [PubMed: 8786014]
481.
Maraschin JdF, Weinert LS, Murussi N, Witter V, Rodrigues TdC, Rossato ER, et al. Influence of age at diagnosis and duration of diabetes on the positivity of glutamic acid decarboxylase antibody in South-Brazilian type 1 diabetes mellitus. Annals of Clinical Biochemistry. 2013;50(Pt 3):262–266. [PubMed: 23610212]
482.
Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007;30(2):210–216. [PubMed: 17259483]
483.
Marshall SM, Collins A, Gregory W, Goodwin A, Hill C, Jarrett RJ, et al. Predictors of the development of microalbuminuria in patients with type I diabetes mellitus: A seven-year prospective study. Diabetic Medicine. 1999;16(11):918–925. [PubMed: 10588521]
484.
Mathiesen ER, Feldt-Rasmussen B, Hommel E, Deckert T, Parving HH. Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. A 5-year prospective study. Diabetes Care. 1997;20(3):286–289. [PubMed: 9051373]
485.
Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. Journal of Clinical Endocrinology and Metabolism. 2013;98(3):1154–1162. [PMC free article: PMC3612802] [PubMed: 23393185]
486.
Matteucci E, Cinapri V, Quilici S, Lucchetti A, Mugnaini P, Giampietro O. Screening for coeliac disease in families of adults with Type 1 diabetes based on serological markers. Diabetes, Nutrition and Metabolism - Clinical and Experimental. 2001;14(1):37–42. [PubMed: 11345164]
487.
Maurizi AR, Lauria A, Maggi D, Palermo A, Fioriti E, Manfrini S, et al. A novel insulin unit calculator for the management of type 1 diabetes. Diabetes Technology and Therapeutics. 2011;13(4):425–428. [PubMed: 21355727]
488.
Maxwell AE, Hunt IF, Bush MA. Effects of a social support group, as an adjunct to diabetes training, on metabolic control and psychosocial outcomes. Diabetes Educator. 1992;18(4):303–309. [PubMed: 1628531]
489.
McAlister FA, Zarnke KB, Campbell NRC, Feldman RD, Levine M, Mahon J, et al. The 2001 Canadian recommendations for the management of hypertension: Part two - Therapy. Canadian Journal of Cardiology. 2002;18(6):625–641. [PubMed: 12107420]
490.
Mccallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–467. [PubMed: 6400707]
491.
Mccallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clinical Gastroenterology and Hepatology. 2010;8(11):947–954. [PubMed: 20538073]
492.
McCavert M, Mone F, Dooher M, Brown R, O'Donnell ME. Peri-operative blood glucose management in general surgery - a potential element for improved diabetic patient outcomes -an observational cohort study. International Journal of Surgery. 2010;8(6):494–498. [PubMed: 20621207]
493.
McClean MT, Andrews WJ, McElnay JC. Characteristics associated with neuropathy and/or retinopathy in a hospital outpatient diabetic clinic. Pharmacy World and Science. 2005;27(3):154–158. [PubMed: 16096880]
494.
McCulloch DK. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes… Diabetes Spectrum. 1996;9(3):180–181. [commentary on Levetan CS, Salas R, Wiltes IF et al. Am.J.Med. 99:22-8, 1995]
495.
McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. A prospective comparison of ‘conventional’ and high carbohydrate/high fibre/low fat diets in adults with established type 1 (insulin-dependent) diabetes. Diabetologia. 1985;28(4):208–212. [PubMed: 2991051]
496.
McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabetic Medicine. 2011;28(9):1028–1033. [PubMed: 21395678]
497.
McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research and Opinion. 2007;23(Suppl.1):S7–S19.
498.
McGill M, Constantino M, Yue DK. Integrating telemedicine into a National Diabetes Footcare Network. Practical Diabetes International. 2000;17(7):235–238.
499.
McHardy KC, Gann ME, Ross IS, Pearson DW. A simple approach to screening for microalbuminuria in a type 1 (insulin-dependent) diabetic population. Annals of Clinical Biochemistry. 1991;28(Pt 5):450–455. [PubMed: 1958047]
500.
Mckay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technology and Therapeutics. 2009;11(3):195–201. [PubMed: 19267582]
501.
McQueen RB, Ellis SL, Campbell JD, Nair K, Sullivan PW V. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Effectiveness and Resource Allocation. 2011;9:13–21. [PMC free article: PMC3180394] [PubMed: 21917132]
502.
Medicines and Healthcare products Regulatory Agency, Commission on Human Medicines. Aspirin: not licensed for primary prevention of thrombotic vascular disease. Drug Safety Update. 2014;3(3):10.
503.
Merimee TJ, Gardner DF, Zapf J, Froesch ER. Effect of glycemic control on serum insulin-like growth factors in diabetes mellitus. Diabetes. 1984;33(8):790–793. [PubMed: 6378701]
504.
Meyer C, Hering BJ, Grossmann R, Brandhorst H, Brandhorst D, Gerich J, et al. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation. 1998;66(2):233–240. [PubMed: 9701271]
505.
Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care. 2002;25(12):2153–2158. [PubMed: 12453953]
506.
Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between the frequency of selfmonitoring of blood glucose and haemoglobin A1c levels in type 1 diabetes exchange participants. Diabetes Care. 2013;36(7):2009–2014. [PMC free article: PMC3687326] [PubMed: 23378621]
507.
Minder AE, Albrecht D, Schafer J, Zulewski H. Frequency of blood glucose testing in well educated patients with diabetes mellitus type 1: How often is enough? Diabetes Research and Clinical Practice. 2013;101(1):57–61. [PubMed: 23726303]
508.
Miwa T, Itoh R, Kobayashi T, Tanabe T, Shikuma J, Takahashi T, et al. Comparison of the effects of a new 32-Gaugex4-mm pen needle and a 32-Gaugex6-mm pen needle on glycemic control, safety, and patient ratings in japanese adults with diabetes. Diabetes Technology and Therapeutics. 2012;14(12):1084–1090. [PubMed: 23030357]
509.
Miyakoshi M, Kamoi K, Iwanaga M, Hoshiyama A, Yamada A. Comparison of patient's preference, pain perception, and usability between Micro Fine Plus 31-gauge needle and Microtapered NanoPass 33-gauge needle for insulin therapy. Journal of Diabetes Science and Technology. 2007;1(5):718–724. [PMC free article: PMC2769671] [PubMed: 19885140]
510.
Moheet A, Kumar A, Chow L, Eberly LE, Seaquist ER. History of severe hypoglycemia and score on clarke questionnaire is associated with blunted counterregulatory response to experimental hypoglycemia in patients with type 1 diabetes. Diabetes. 2012;61(Suppl.1):A99.
511.
Mok PH, Cheng MW. Outcomes and perceptions of 4mm pen needle use in diabetes patients: Results from a multi-center survey pilot study in Hong Kong. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2012;15(7):A664.
512.
Monge L, Bruno G, Pinach S, Grassi G, Maghenzani G, Dani F, et al. A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years. Diabetic Medicine. 2004;21(5):456–459. [PubMed: 15089790]
513.
Morris DB. A rural diabetes support group. Diabetes Educator. 1998;24(4):493–497. [PubMed: 9830953]
514.
Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Annals of Internal Medicine. 1986;105(6):836–840. [PubMed: 3096181]
515.
Moss SE, Klein R, Klein BE. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999;22(6):951–959. [PubMed: 10372248]
516.
Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Archives of Internal Medicine. 1994;154(21):2473–2479. [PubMed: 7979844]
517.
Mota MC, Leite E, Ruas MA, Verjans HL, Blakemore CB, Cunha-Vaz JG. Effect of cyclospasmol on early diabetic retinopathy. International Ophthalmology. 1987;10(1):3–9. [PubMed: 3549595]
518.
Muhlhauser I, Overmann H, Bender R, Bott U, Berger M. Risk factors of severe hypoglycaemia in adult patients with Type I diabetes--a prospective population based study. Diabetologia. 1998;41(11):1274–1282. [PubMed: 9833933]
519.
Murao S, Kondo S, Ohashi J, Fujii Y, Shimizu I, Fujiyama M, et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)--a 5-year follow-up of the Ehime study. Diabetes Research and Clinical Practice. 2008;80(1):114–121. [PubMed: 18342387]
520.
Nagai Y, Ohshige T, Arai K, Kobayashi H, Sada Y, Ohmori S, et al. Comparison between shorter straight and thinner microtapered insulin injection needles. Diabetes Technology and Therapeutics. 2013;15(7):550–555. [PubMed: 23621793]
521.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine. 2005;353(25):2643–2653. [PMC free article: PMC2637991] [PubMed: 16371630]
522.
Nathan DM, McKitrick C, Larkin M, Schaffran R, Singer DE. Glycemic control in diabetes mellitus: have changes in therapy made a difference? American Journal of Medicine. 1996;100(2):157–163. [PubMed: 8629649]
523.
Nathan DM., DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. [PMC free article: PMC3867999] [PubMed: 24356592]
524.
Nathan DM, McGee P, Steffes MW, Lachin JM. DCCT/EDIC Research Group. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63(1):282–290. [PMC free article: PMC3868040] [PubMed: 23990364]
525.
National Collaborating Centre for Women's and Children's Health. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. London: RCOG Press; 2008. (NICE clinical guideline 63). Available from: http://guidance​.nice.org.uk/CG63. [PubMed: 21370515]
526.
National Institute for Health and Care Excellence. Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. London: National Institute for Health and Care Excellence; 2013. (NICE clinical guideline 173). Available from: http://guidance​.nice.org.uk/CG173.
527.
National Institute for Health and Clinical Excellence. Diabetes type 1 and 2: the clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes. London: National Institute for Health and Clinical Excellence; 2002. (NICE technology appraisal guidance 53). Available from: http://www​.nice.org.uk/TA053.
528.
National Institute for Health and Clinical Excellence. The clinical effectiveness and cost effectiveness of patient education models for diabetes. London: National Institute for Health and Clinical Excellence; 2003. (NICE technology appraisal guidance 60). Available from: http://guidance​.nice.org.uk/TA60.
529.
National Institute for Health and Clinical Excellence. Diagnosis and management of type 1 diabetes in children, young people and adults. London: NICE; 2004. Available from: http://guidance​.nice.org.uk/CG15.
530.
National Institute for Health and Clinical Excellence. Costing report Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition. London: National Institute for Health and Clinical Excellence; 2006. (NICE clinical guideline 32).
531.
National Institute for Health and Clinical Excellence. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. London: National Institute for Health and Clinical Excellence (NICE); 2008. (NICE interventional procedure guidance 257). Available from: http://www​.nice.org.uk/IPG257.
532.
National Institute for Health and Clinical Excellence. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. London: National Institute for Health and Clinical Excellence (NICE); 2008. (NICE interventional procedure guidance 257). Available from: http://www​.nice.org.uk/IPG257.
533.
National Institute for Health and Clinical Excellence. Diabetes in adults. 2011. [8 October 2014]. (NICE quality standard 6). Available from: http://guidance​.nice.org.uk/QS6.
534.
National Institute for Health and Clinical Excellence. Management of hyperglycaemia in people with acute coronary syndromes. London: National Institute for Health and Clinical Excellence; 2011. (NICE clinical guideline 130). Available from: http://guidance​.nice.org.uk/CG130.
535.
National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications​.nice​.org.uk/the-guidelines-manual-pmg6/ [PubMed: 27905714]
536.
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2nd edition. London: National Institute for Health and Clinical Excellence; 2013. Available from: http://publications​.nice.org.uk/pmg9. [PubMed: 27905712]
537.
National Patient Safety Agency. The adult patient's passport to safer use of insulin. 2011. [11 September 2014]. Available from: http://www​.nrls.npsa​.nhs.uk/resources/?EntryId45=130397.
538.
Nayak AU, Holland MR, Viswanath AK, Singh BM. HbA1c may not accurately reflect glycaemia in diabetes-examina tion of the relationship between HbA1c and self blood glucose monitoring independent of glycation gap. Diabetes. 2011;60(Suppl.1):A245.
539.
Newman SP, Cooke D, Casbard A, Walker S, Meredith S, Nunn A, et al. A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). Health Technology Assessment. 2009;13(28):1–194. [PubMed: 19476724]
540.
NHS Business Services Authority NHS Electronic Drug Tariff: December 2013. 2013. [12 December 2013]. Available from: http://www​.ppa.org.uk​/edt/December_2013/mindex.htm.
541.
NHS Business Services Authority NHS Electronic Drug Tariff: November 2014 2014Available from: http://www​.ppa.org.uk​/edt/November_2014/mindex.htmNovember 2014]
542.
NHS Centre for Reviews and Dissemination. Aspirin for the secondary prophylaxis of vascular disease in primary care. York: University of York, Centre for Health Economics; 1998. University of Newcastle upon Tyne, Centre for Health Services Research. Available from: http://www​.ncl.ac.uk​/chsr/publications/guide/aspirin.pdf.
543.
NHS Diabetes and Royal College of General Practitioners. Coding, classification and diagnosis of diabetes: A review of the coding, classification and diagnosis of diabetes in primary care in England with recommendations for improvement. London: Department of Health; 2011.
544.
NHS England. UK Islet cell transplantation service specifications (contract A17/S(NHSS)c. NHS England; 2013. Available from: http://www​.england.nhs​.uk/wp-content/uploads​/2013/06/a17-islet-trans-serv-ad.pdf.
545.
NICE. Management of type 2 diabetes: Retinopathy - screening and early management. London: NICE; 2002. Available from: http://www​.wales.nhs​.uk/sites3/documents​/334/diabetesretinopathyguideline.pdf.
546.
Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid. 2006;16(6):573–582. [PubMed: 16839259]
547.
Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI, Parving HH. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 1995;38(5):592–598. [PubMed: 7489843]
548.
Nielsen JK, Gravholt CH, Djurhuus CB, Brandt D, Becker J, Heinemann L, et al. Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. Journal of Diabetes Science and Technology. 2007;1(6):857–863. [PMC free article: PMC2769673] [PubMed: 19885157]
549.
Nielsen S. Eating disorders in females with type 1 diabetes: An update of a meta-analysis. European Eating Disorders Review. 2002;10(4):241–254.
550.
Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications--the Linkoping Diabetes Complications Study. Pediatric Diabetes. 2009;10(3):168–176. [PubMed: 19175900]
551.
Nuffield Trust. Sharing,Stories: a feasibility study of facilitated small group learning by the oral tradition in diabetes education for British Bangladesh's in Tower Hamlets. 2000.
552.
Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism: Clinical and Experimental. 1999;48(7):935–941. [PubMed: 10421239]
553.
O'Connell MA, Donath S, O'Neal DN, Colman PG, Ambler GR, Jones TW, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009;52(7):1250–1257. [PubMed: 19396424]
554.
Olausson EA, Alpsten M, Larsson A, Mattsson H, Andersson H, Attvall S. Small particle size of a solid meal increases gastric emptying and late postprandial glycaemic response in diabetic subjects with gastroparesis. Diabetes Research and Clinical Practice. 2008;80(2):231–237. [PubMed: 18237818]
555.
Olausson EA, Storsrud S, Grundin H, Isaksson M, Attvall S, Simren M. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. American Journal of Gastroenterology. 2014;109(3):375–385. [PubMed: 24419482]
556.
Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism: Clinical and Experimental. 2002;51(2):248–254. [PubMed: 11833057]
557.
Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline KL, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003;26(5):1374–1379. [PubMed: 12716791]
558.
Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2011. [16 October 2014]. Available from: http://www​.oecd.org/std/ppp.
559.
Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. [17 October 2014]. Available from: http://www​.oecd.org/std/ppp.
560.
Ostwald SK, Hepburn KW, Caron W, Burns T. Reducing caregiver burden: a randomised psychoeducational intervention for caregivers of persons with dementia. Gerontologist. 1999;39(3):299–309. [PubMed: 10396888]
561.
Ota T, Takamura T, Nagai Y, Bando Y, Usuda R. Significance of IA-2 antibody in Japanese type 1 diabetes: its association with GAD antibody. Diabetes Research and Clinical Practice. 2005;67(1):63–69. [PubMed: 15620435]
562.
Pagani A, Greco G, Tagliaferro V, Marena S, Pagano G. Dipyridamole administration in insulin-dependent diabetics with background retinopathy: A 36-month follow-up. Current Therapeutic Research, Clinical & Experimental. 1989;45(3):469–475.
563.
Palma CCSS, Pavesi M, Nogueira VG, Clemente ELS, Vasconcellos MDFB, Pereira LC, et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetology and Metabolic Syndrome. 2013;5(1) [PMC free article: PMC3852595] [PubMed: 24499529]
564.
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion. 2004;20(S1):S5–S26. [PubMed: 15324513]
565.
Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for Type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Current Medical Research and Opinion. 2004;20(11):1729–1746. [PubMed: 15537473]
566.
Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweizerische Medizinische Wochenscrift. 2000;130(27-28):1034–1040. [PubMed: 10953853]
567.
Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, et al. An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK. Current Medical Research and Opinion. 2007;23(4):895–901. [PubMed: 17407646]
568.
Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia. 2000;43(1):13–26. [PubMed: 10672449]
569.
Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabetic Medicine. 2002;19(4):285–291. [PubMed: 11942999]
570.
Paschke A, Grzelka A, Zawada A, Zozulinska-Ziolkiewicz D. Clinical characteristics and autoantibody pattern in newly diagnosed adult-onset autoimmune diabetes. Polskie Archiwum Medycyny Wewnetrznej. 2013;123(7-8):401–408. [PubMed: 23792409]
571.
Patrick AW, Collier A, Hepburn DA, Steedman DJ, Clarke BF, Robertson C. Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department. Archives of Emergency Medicine. 1990;7(2):73–77. [PMC free article: PMC1285671] [PubMed: 2390157]
572.
Patterson D. A multicenter placebo-controlled study of dompiderone in diabetic gastroparesis. Gastroenterology. 1993;104(A564)
573.
Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. American Journal of Gastroenterology. 1999;94(5):1230–1234. [PubMed: 10235199]
574.
Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2003;19(3):232–240. [PubMed: 12789657]
575.
Pegoraro A, Singh A, Bakir AA, Arruda JA, Dunea G. Simplified screening for microalbuminuria. Annals of Internal Medicine. 1997;127(9):817–819. [PubMed: 9382403]
576.
Perez Mendez LF, Alvarez-Garcia E, Alvarez-Vazquez P, Hervas E, Casteras A, Fajar L, et al. Long-term improvement of metabolic control without increased risk of hypoglycaemia by intensive insulin regimens in type 1 diabetes patients treated in a regular clinical setting. Experimental and Clinical Endocrinology & Diabetes. 2007;115(3):182–186. [PubMed: 17427108]
577.
Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabetic Medicine. 1995;12(7):622–627. [PubMed: 7554786]
578.
Perry TL, Mann JI, Lewis-Barned NJ, Duncan AW, Waldron MA, Thompson C. Lifestyle intervention in people with insulin-dependent diabetes mellitus (IDDM). European Journal of Clinical Nutrition. 1997;51:757–763. [PubMed: 9368810]
579.
Pfohl M, Schadlich PK, Dippel FW, Koltermann KC. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. Journal of Medical Economics. 2012;15(Suppl.2):14–27. [PubMed: 22812690]
580.
Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Experimental and Clinical Endocrinology. 1996;104(1):25–30. [PubMed: 8750567]
581.
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805. [PMC free article: PMC3131116] [PubMed: 21737469]
582.
Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabetic Medicine. 2005;22(7):850–857. [PubMed: 15975098]
583.
Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care. 2000;23(2):157–162. [PubMed: 10868824]
584.
Piehlmeier W, Renner R, Kimmerling T, Schramm W, Garbe S, Proetzsch R, et al. Evaluation of the Micral-Test S, a qualitative immunologic patient self-test for microalbuminuria: the PROSIT project. Proteinuria Screening and Intervention. Diabetic Medicine. 1998;15(10):883–885. [PubMed: 9796891]
585.
Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN. Screening and treating adults for lipid disorders. American Journal of Preventive Medicine. 2001;20(3:Suppl):77–89. [PubMed: 11306236]
586.
Piters KM, Kumar D, Pei E, Bessman AN. Comparison of continuous and intermittent intravenous insulin therapies for diabetic ketoacidosis. Diabetologia. 1977;13(4):317–321. [PubMed: 21119]
587.
Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, et al. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obesity and Metabolism. 2013;15(5):427–431. [PubMed: 23167274]
588.
Piwernetz K, Renner R, Mohrlein A, Steiner M, Hepp KD, Engelbrecht R, et al. Analysis and processing of data in a hospital-based diabetes management system. Hormone and Metabolic Research Supplement Series. 1990;24:109–115. [PubMed: 2272615]
589.
Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107–1112. [PubMed: 15855574]
590.
Poggioli R, Faradji RN, Ponte G, Betancourt A, Messinger S, Baidal DA, et al. Quality of life after islet transplantation. American Journal of Transplantation. 2006;6(2):371–378. [PubMed: 16426323]
591.
Polak BC, Crijns H, Casparie AF, Niessen LW. Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy. Health Policy. 2003;64(1):89–97. [PubMed: 12644331]
592.
Poppe AY, Vautour L, Yale J-F, Wing SS. Evaluation of a protocol for the perioperative administration of intravenous insulin in patients with diabetes. Canadian Journal of Diabetes. 2004;28(2):134–141.
593.
Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabetic Medicine. 2004;21(11):1213–1220. [PubMed: 15498088]
594.
Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ. An estimation of the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK. Diabetic Medicine. 2009;26(8):803–814. [PMC free article: PMC3228293] [PubMed: 19709151]
595.
Prazny M, Skrha J, Limanova Z, Hilgertova J. The evaluation of thyroid and islet autoantibodies in type 1 diabetes mellitus. Sbornik Lekarsky. 1999;100(3):205–211. [PubMed: 11221467]
596.
Preiser JC, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Medicine. 2009;35(10):1738–1748. [PubMed: 19636533]
597.
Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009;32(12):2245–2250. [PMC free article: PMC2782985] [PubMed: 19767384]
598.
Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes & Metabolism. 2010;36(5):409–413. [PubMed: 20864372]
599.
Radtke MA, Midthjell K, Nilsen TIL, Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study. Diabetes Care. 2009;32(2):245–250. [PMC free article: PMC2628687] [PubMed: 19001190]
600.
Rajalakshmi R, Amutha A, Ranjani H, Ali MK, Unnikrishnan R, Anjana RM, et al. Prevalence and risk factors for diabetic retinopathy in Asian Indians with young onset type 1 and type 2 diabetes. Journal of Diabetes and Its Complications. 2014;28(3):291–297. [PubMed: 24512748]
601.
Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999;13(9):569–592. [PubMed: 10482967]
602.
Rankin D, Elliott J, Heller S, Amiel S, Rogers H, DeZoysa N, et al. Experiences of hypoglycaemia unawareness amongst people with Type 1 diabetes: A qualitative investigation. Chronic Illness. 2013;10(3):180–191. [PubMed: 24302225]
603.
Rapid Reviews Team SHc. Patient education models for diabetes. Southampton: NICE; 2002. Available from: http://www​.nice.org.uk​/guidance/ta60/resources​/assessment-report-patient-education-models-for-diabetes-2.
604.
Raskin P, Ganda OP, Schwartz S, Willard D, Rosenstock J, Lodewick PA, et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. American Journal of Medicine. 1995;99(4):362–369. [PubMed: 7573090]
605.
Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583–588. [PubMed: 10834413]
606.
Raskin P, Klaff L, Bergenstal R, Halle J-P, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23(11):1666–1671. [PubMed: 11092290]
607.
Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic Medicine. 2004;21(11):1204–1212. [PubMed: 15498087]
608.
Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23(5):639–643. [PubMed: 10834423]
609.
Rattarasarn C, Diosdado MA, Ortego J, Leelawattana R, Soonthornpun S, Setasuban W, et al. Thyroid autoantibodies in Thai type 1 diabetic patients: clinical significance and their relationship with glutamic acid decarboxylase antibodies. Diabetes Research and Clinical Practice. 2000;49(2-3):107–111. [PubMed: 10963821]
610.
Ray T, Choudhary P, Mansell P, Heller S, Amiel SA, Hopkins D. Dose adjustment for normal eating (DAFNE) structured education reduces progression to continuous subcutaneous insulin infusion (CSII) among patients being considered for insulin pump therapy at enrolment. Diabetic Medicine. 2013;30(Suppl.1):7–8.
611.
Reichard P. Are there any glycemic thresholds for the serious microvascular diabetic complications? Journal of Diabetes and Its Complications. 1995;9(1):25–30. [PubMed: 7734740]
612.
Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine. 1993;329(5):304–309. [PubMed: 8147960]
613.
Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia. 1996;39(12):1483–1488. [PubMed: 8960830]
614.
Renard E, Dubois-Laforgue D, Guerci B. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: A multicenter, randomized, crossover study. Diabetes Technology and Therapeutics. 2011;13(12):1213–1218. [PubMed: 21810024]
615.
Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421–426. [PubMed: 9952201]
616.
Reviriego J, Gomis R, Maranes JP, Ricart W, Hudson P. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. International Journal of Clinical Practice. 2008;62(7):1026–1032. [PMC free article: PMC2438603] [PubMed: 18489577]
617.
Riazi A, Hammersley S, Eiser C, Eiser JR, Tooke JE. Patients' experiences of the diabetes annual review. Practical Diabetes International. 2000;17(7):226–230.
618.
Ricci DA, Saltzman MB, Meyer C, Callachan C, Mccallum RW. Effect of metoclopramide in diabetic gastroparesis. Journal of Clinical Gastroenterology. 1985;7(1):25–32. [PubMed: 3884697]
619.
Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, et al. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clinical Therapeutics. 2004;26(4):502–510. [PubMed: 15189747]
620.
Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. International Journal of Clinical Practice. 2001;55(3):177–182. [PubMed: 11351771]
621.
Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clinical Therapeutics. 1999;21(3):523–534. [PubMed: 10321421]
622.
Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care. 1996;19(10):1051–1061. [PubMed: 8886549]
623.
Rodin G, Olmsted MP, Rydall AC, Maharaj SI, Colton PA, Jones JM, et al. Eating disorders in young women with type 1 diabetes mellitus. Journal of Psychosomatic Research. 2002;53(4):943–949. [PubMed: 12377307]
624.
Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;23:2767–2771. [PubMed: 11733392]
625.
Rogers HA, de ZN, Amiel SA. Patient experience of hypoglycaemia unawareness in Type 1 diabetes: are patients appropriately concerned? Diabetic Medicine. 2012;29(3):321–327. [PubMed: 21913969]
626.
Rogowicz-Frontczak A, Zozulilska-Ziolkiewicz D, Litwinowicz M, Niedzwiecki P, Wyka K, Wierusz-Wysocka B. Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes? European Journal of Endocrinology. 2014;170(4):651–658. [PubMed: 24480135]
627.
Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetologica. 2013;50(2):129–134. [PubMed: 20953640]
628.
Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care. 2000;23(8):1137–1142. [PubMed: 10937511]
629.
Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003;26(5):1490–1496. [PubMed: 12716810]
630.
Rossi MC, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, et al. Diabetes Interactive Diary: a new telemedicine system enabling flexible diet and insulin therapy while improving quality of life: an open-label, international, multicenter, randomized study. Diabetes Care. 2010;33(1):109–115. [PMC free article: PMC2797954] [PubMed: 19808926]
631.
Rossi MC, Nicolucci A, Lucisano G, Pellegrini F, Di Bartolo P, Miselli V, et al. Impact of the “diabetes interactive diary” telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes. Diabetes Technology and Therapeutics. 2013;15(8):670–679. [PubMed: 23844569]
632.
Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996;313(7060):779–784. [PMC free article: PMC2352213] [PubMed: 8842069]
633.
Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal–bolus regimen. Clinical Therapeutics. 2004;26(5):724–736. [PubMed: 15220016]
634.
Rustemeijer C, Schouten JA, Janssens ENW, Spooren PFM, van Doormaal JJ. Pravastatin in diabetes associated hypercholesterolemia. Acta Diabetologica. 1997;34(4):294–300. [PubMed: 9451475]
635.
Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–2069. [PubMed: 15983207]
636.
Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–962. [PubMed: 15047610]
637.
Ryan EA, Germsheid J. Use of continuous glucose monitoring system in the management of severe hypoglycemia. Diabetes Technology and Therapeutics. 2009;11(10):635–639. [PubMed: 19821755]
638.
Ryder J, Cavan DA, Ziegler R, Cranston I, Barnard K, Vogel C, et al. Use of an automated bolus advisor may improve carbohydrate counting competence in patients treated with multiple daily insulin injection therapy: Results from ABACUS. Diabetologia. 2013;56:S425.
639.
Ryder REJ, Dent MT, Ward JD. Testing for diabetic neuropathy, part two: Autonomic neuropathy. Practical Diabetes. 1992;9(2):56–60.
640.
Sacks HS, Shahshahani M, Kitabchi AE, Fisher JN, Young RT. Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. Annals of Internal Medicine. 1979;90(1):36–42. [PubMed: 105656]
641.
Sadur CN, Moline N, Costa M, Michalik D, Mendlowitz D, Roller S, et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care. 1999;22:2011–2017. [PubMed: 10587835]
642.
Saenz dT I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159–2164. [PubMed: 12453954]
643.
Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Journal of Diabetes and Its Complications. 2004;18(4):205–210. [PubMed: 15207837]
644.
Samann A, Muhlhauser I, Bender R, Kloos C, Muller UA. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia. 2005;48(10):1965–1970. [PubMed: 16132954]
645.
Samsom M, Jebbink RJ, Akkermans LM, Bravenboer B, van Berge-Henegouwen GP, Smout AJ. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care. 1997;20(2):129–134. [PubMed: 9118759]
646.
Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. American Journal of Physiology, Gastrointestinal and Liver Physiology. 2000;278(6):G946–G951. [PubMed: 10859225]
647.
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014;37(3):666–670. [PMC free article: PMC3931382] [PubMed: 24194508]
648.
Sartor G, Katzman P, Eizyk E, Kalen J, Nilsson A, Ugander L, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics. 1995;33(1):3–6. [PubMed: 7711988]
649.
Sategna-Guidetti C, Grosso S, Pulitano R, Benaduce E, Dani F, Carta Q. Celiac disease and insulin-dependent diabetes mellitus. Screening in an adult population. Digestive Diseases and Sciences. 1994;39(8):1633–1637. [PubMed: 8050311]
650.
Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JAE, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabetic Medicine. 2011;28(5):508–515. [PubMed: 21255074]
651.
Scavone G, Manto A, Pitocco D, Gagliardi L, Caputo S, Mancini L, et al. Effect of carbohydrate counting and medical nutritional therapy on glycaemic control in Type 1 diabetic subjects: a pilot study. Diabetic Medicine. 2010;27(4):477–479. [PubMed: 20536522]
652.
Schachinger H, Hegar K, Hermanns N, Straumann M, Keller U, Fehm-Wolfsdorf G, et al. Randomized controlled clinical trial of blood glucose awareness training (BGAT III) in Switzerland and Germany. Journal of Behavioral Medicine. 2005;28(6):587–594. [PubMed: 16222412]
653.
Schafer LC, McCaul KD, Glasgow RE. Supportive and nonsupportive family behaviors: relationships to adherence and metabolic control in persons with type I diabetes. Diabetes Care. 1986;9:179–185. [PubMed: 3698784]
654.
Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diabetes Care. 1998;21(4):570–573. [PubMed: 9571344]
655.
Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care. 1982;5(5):479–484. [PubMed: 6765224]
656.
Schmidt S, Meldgaard M, Serifovski N, Storm C, Christensen TM, Gade-Rasmussen B, et al. Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study. Diabetes Care. 2012;35(5):984–990. [PMC free article: PMC3329826] [PubMed: 22344610]
657.
Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care. 1992;15(11):1800–1810. [PubMed: 1468318]
658.
Scholin A, Bjorklund L, Borg H, Arnqvist H, Bjork E, Blohme G, et al. Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden. Journal of Internal Medicine. 2004;255(3):384–391. [PubMed: 14871463]
659.
Scholin A, Nystrom L, Arnqvist H, Bolinder J, Bjork E, Berne C, et al. Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults. Diabetic Medicine. 2011;28(2):156–161. [PubMed: 21219422]
660.
Scholin A, Torn C, Nystrom L, Berne C, Arnqvist H, Blohme G, et al. Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in Type 1 diabetes. Diabetic Medicine. 2004;21(5):447–455. [PubMed: 15089789]
661.
Scholin A, Siegbahn A, Lind L, Berne C, Sundkvist G, Bjork E, et al. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2004;20(3):205–210. [PubMed: 15133751]
662.
Schopman JE, Geddes J, Frier BM. Frequency of symptomatic and asymptomatic hypoglycaemia in Type 1 diabetes: effect of impaired awareness of hypoglycaemia. Diabetic Medicine. 2011;28(3):352–355. [PubMed: 21309845]
663.
Schutt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Experimental and Clinical Endocrinology & Diabetes. 2006;114(7):384–388. [PubMed: 16915542]
664.
Schwartz SL, Hanson C, Lucas C, Rosenblatt S, Rosenstock J, Whittier F, et al. Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension. Clinical Therapeutics. 1993;15(1):79–87. [PubMed: 8458057]
665.
Scottish Intercollegiate Guidelines Network. Lipids and the primary prevention of coronary heart disease. SIGN; 1999. Available from: http://www​.nhsggc.org​.uk/content/mediaassets/pdf/HSD/sign40​.pdf.
666.
Scottish Intercollegiate Guidelines Network. Hypertension in older people; Treatment of special groups of older people. SIGN; 2001. Available from: http://www​.nhsggc.org​.uk/content/mediaassets/pdf/HSD/sign49​.pdf.
667.
Scottish Intercollegiate Guidelines Network. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2001. Management of diabetes. (SIGN Publication 55).
668.
Scottish Intercollegiate Guidelines Network Management of diabetes: a national clinical guideline Edinburgh: SIGN,2010Available from: http://www​.sign.ac.uk/pdf/sign116.pdf.
669.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–1395. [PMC free article: PMC3631867] [PubMed: 23589542]
670.
Sequeira PA, Montoya L, Ruelas V, Xing D, Chen V, Beck R, et al. Continuous glucose monitoring pilot in low-income type 1 diabetes patients. Diabetes Technology and Therapeutics. 2013;15(10):855–858. [PMC free article: PMC3781124] [PubMed: 23865840]
671.
Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia. 2001;44(10):1215–1220. [PubMed: 11692169]
672.
Service FJ, O'Brien PC. Influence of glycemic variables on hemoglobin A1c. Endocrine Practice. 2007;13(4):350–354. [PubMed: 17669710]
673.
Shaban MC, Fosbury J, Kerr D, Cavan DA. The prevalence of depression and anxiety in adults with Type 1 diabetes. Diabetic Medicine. 2006;23(12):1381–1384. [PubMed: 17116192]
674.
Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. New England Journal of Medicine. 2006;355(13):1318–1330. [PubMed: 17005949]
675.
Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. New England Journal of Medicine. 2006;355(13):1318–1330. [PubMed: 17005949]
676.
Sharma D, Morrison G, Joseph F, Purewal TS, Weston PJ. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia. 2011;54(11):2768–2770. [PubMed: 21842427]
677.
Shearer A, Bagust A, Sanderson D, Heller S, Roberts S. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK. Diabetic Medicine. 2004;21(5):460–467. [PubMed: 15089791]
678.
Shephard MD, Barratt LJ, Simpson-Lyttle W. Is the Bayer DCA 2000 acceptable as a screening instrument for the early detection of renal disease? Annals of Clinical Biochemistry. 1999;36(Pt 3):393–394. [PubMed: 10376085]
679.
Shimizu H, Uehara Y, Okada S, Mori M. Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients. Endocrine Journal. 2008;55(4):753–756. [PubMed: 18497454]
680.
Shishikura K, Tanimoto K, Sakai S, Tanimoto Y, Terasaki J, Hanafusa T. Association between skeletal muscle mass and insulin secretion in patients with type 2 diabetes mellitus. Endocrine Journal. 2014;61(3):281–287. [PubMed: 24420336]
681.
Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews. 2006;(Issue 2) CD003287. [PubMed: 16625575] [CrossRef]
682.
Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. Journal of the American Society of Nephrology. 1992;3(4 Suppl.):S111–S119. [PubMed: 1457753]
683.
Siegmund T, Blankenfeld H, Schumm-Draeger PM. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: “thin-wall” needles compared to “regular-wall” needles: an open-label study. Diabetes Technology and Therapeutics. 2009;11(8):523–528. [PubMed: 19698066]
684.
Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EMM, Mccallum R, et al. Domperidone in the management of symptoms of diabetic gastroparesis: Efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clinical Therapeutics. 1998;20(3):438–453. [PubMed: 9663360]
685.
Simmons D, Morton K, Laughton SJ, Scott DJ. A comparison of two intravenous insulin regimens among surgical patients with insulin-dependent diabetes mellitus. Diabetes Educator. 1994;20(5):422–427. [PubMed: 7851255]
686.
Sjoberg K, Eriksson KF, Bredberg A, Wassmuth R, Eriksson S. Screening for coeliac disease in adult insulin-dependent diabetes mellitus. Journal of Internal Medicine. 1998;243(2):133–140. [PubMed: 9566642]
687.
Sjoberg S, Carlson A, Rosenqvist U, Ostman J. Health attitudes, self-monitoring of blood glucose, metabolic control and residual insulin secretion in type 1 diabetic patients. Diabetic Medicine. 1988;5(5):449–453. [PubMed: 2970918]
688.
Skeie S, Kristensen GBB, Carlsen S, Sandberg S. Self-monitoring of blood glucose in type 1 diabetes patients with insufficient metabolic control: focused self-monitoring of blood glucose intervention can lower glycated hemoglobin A1C. Journal of Diabetes Science and Technology. 2009;3(1):83–88. [PMC free article: PMC2769849] [PubMed: 20046652]
689.
Smith CB, Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care. 2009;32(7):1196–1198. [PMC free article: PMC2699737] [PubMed: 19389817]
690.
Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Annals of Internal Medicine. 2000;132(12):933–937. [PubMed: 10858175]
691.
Smith SA, Murphy ME, Huschka TR, Dinneen SF, Gorman CA, Zimmerman BR, et al. Impact of a diabetes electronic management system on the care of patients seen in a subspecialty diabetes clinic. Diabetes Care. 1998;21(6):972–976. [PubMed: 9614616]
692.
Snape WJ Jr., Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Annals of Internal Medicine. 1982;96(4):444–446. [PubMed: 7065559]
693.
Snoek FJ, Van Der Ven NCW, Twisk JWR, Hogenelst MHE, Tromp-Wever AME, van der Ploeg HM, et al. Cognitive behavioural therapy (CBT) compared with blood glucose awareness training (BGAT) in poorly controlled Type 1 diabetic patients: Long-term effects on HbA1c moderated by depression. A randomized controlled trial. Diabetic Medicine. 2008;25(11):1337–1342. [PubMed: 19046225]
694.
Sorgjerd EP, Skorpen F, Kvaloy K, Midthjell K, Grill V. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway. Diabetologia. 2012;55(5):1310–1318. [PubMed: 22297581]
695.
Speight J, Barendse S, Singh H, Amiel SA, Elliot J, Evans M, et al. The Hypo Awareness Questionnaire: design of a novel measure of awareness of hypoglycaemia for use in the UK Hypo COMPaSS trial. Diabetic Medicine. 2011;28(Suppl.1):181.
696.
Spiess K, Sachs G, Pietschmann P, Prager R. A program to reduce onset distress in unselected type I diabetic patients: effects on psychological variables and metabolic control. European Journal of Endocrinology. 1995;132(5):580–586. [PubMed: 7749498]
697.
Stades AM, Hoekstra JB, van dT I, Erkelens DW, Holleman F., STABILITY Study Group. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults : a real-life design. Diabetes Care. 2002;25(4):712–717. [PubMed: 11919130]
698.
Stadler M, Shuttlewood EM, Rogers H, Gianfrancesco C, Beveridge S, Britneff E, et al. DAFNE-HART, a psycho-educational programme to reverse hypoglycaemia unawareness in Type 1 diabetes: Report on sustained biomedical benefit at 1 year, and the user experience. Diabetic Medicine. 2014;31:8–9.
699.
Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal–bolus therapy for the treatment of type 1 diabetes. Diabetes Technology and Therapeutics. 2004;6(5):579–588. [PubMed: 15628811]
700.
Stern Z, Levy R. Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications. Acta Diabetologica. 1996;33(1):48–52. [PubMed: 8777285]
701.
Stolk EA, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. BMJ (Clinical Research Ed ). 2000;320(7243):1165–1168. [PMC free article: PMC27357] [PubMed: 10784537]
702.
Storms FE, Lutterman JA, van't Laar A. Comparison of efficacy of human and porcine insulin in treatment of diabetic ketoacidosis. Diabetes Care. 1987;10(1):49–55. [PubMed: 3105986]
703.
Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness? Endocrine Practice. 2005;11(2):83–90. [PubMed: 15901522]
704.
Stroebel RJ, Scheitel SM, Fitz JS, Herman RA, Naessens JM, Scott CG, et al. A randomized trial of three diabetes registry implementation strategies in a community internal medicine practice. Joint Commission Journal on Quality Improvement. 2002;28:441–450. [PubMed: 12174408]
705.
Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26(2):279–284. [PubMed: 12547849]
706.
Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, et al. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. Journal of Diabetes & Its Complications. 1992;6(2):123–130. [PubMed: 1611136]
707.
Szepietowska B, Glebocka A, Puch U, Gorska M, Szelachowska M. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus. Archives of Medical Research. 2012;8(3):491–495. [PMC free article: PMC3400915] [PubMed: 22852005]
708.
Tabaei BP, Al Kassab AS, Ilag LL, Zawacki CM, Herman WH. Does microalbuminuria predict diabetic nephropathy? Diabetes Care. 2001;24(9):1560–1566. [PubMed: 11522699]
709.
Tabaei BP, Shillnovak J, Brandle M, Burke R, Kaplan RM, Herman WH. Glycemia and the quality of well-being in patients with diabetes. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 2004;13(6):1153–1161. [PubMed: 15287281]
710.
Taboulet P, Deconinck N, Thurel A, Haas L, Manamani J, Porcher R, et al. Correlation between urine ketones (acetoacetate) and capillary blood ketones (3-beta-hydroxybutyrate) in hyperglycaemic patients. Diabetes & Metabolism. 2007;33(2):135–139. [PubMed: 17320448]
711.
Talal AH, Murray JA, Goeken JA, Sivitz WI. Celiac disease in an adult population with insulin-dependent diabetes mellitus: Use of endomysial antibody testing. American Journal of Gastroenterology. 1997;92(8):1280–1284. [PubMed: 9260789]
712.
Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Research and Clinical Practice. 2001;54(2):105–114. [PubMed: 11640994]
713.
Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine. 2008;359(14):1464–1476. [PubMed: 18779236]
714.
Tan HK, Flanagan DE. Impaired hypoglycaemia awareness in Type 1 diabetes in an outpatient setting. Diabetic Medicine. 2012;29(Suppl.1):130.
715.
Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clinic Proceedings. 2004;79(12):1521–1526. [PubMed: 15595336]
716.
Taylor R. Practical community screening for diabetic retinopathy using the mobile retinal camera: report of a 12 centre study. British Diabetic Association Mobile Retinal Screening Group. Diabetic Medicine. 1996;13(11):946–952. [PubMed: 8946152]
717.
Taylor TN, Chrischilles EA. Economic evaluation of interventions in endocrinology. Endocrinology and Metabolism Clinics of North America. 1997;26(1):67–87. [PubMed: 9074853]
718.
Terent A, Hagfall O, Cederholm U. The effect of education and self-monitoring of blood glucose on glycosylated hemoglobin in type I diabetes. A controlled 18-month trial in a representative population. Acta Medica Scandinavica. 1985;217(1):47–53. [PubMed: 3883704]
719.
Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC. Comparative Effectiveness of Basal– bolus Versus Premix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial. Journal of Clinical Endocrinology and Metabolism. 2012;97(10):3504–3514. [PubMed: 22851487]
720.
Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care. 2012;35(6):1206–1212. [PMC free article: PMC3357216] [PubMed: 22432108]
721.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329(14):977–986. [PubMed: 8366922]
722.
The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276(17):1409–1415. [PubMed: 8892716]
723.
The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Archives of Ophthalmology. 1990;108(11):1577–1583. [PubMed: 2244843]
724.
Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. Diabetic Medicine. 2007;24(7):778–783. [PubMed: 17535290]
725.
Thompson DM, Kozak SE, Sheps S. Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: a randomized trial. Canadian Medical Association Journal. 1999;161(8):959–962. [PMC free article: PMC1230704] [PubMed: 10551191]
726.
Thompson RG, Pearson L, Kolterman OG. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997;40(11):1278–1285. [PubMed: 9389419]
727.
Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes. 1997;46(4):632–636. [PubMed: 9075803]
728.
Tildesley HD, Johns KW. Long-term treatment of type 1 diabetes in the outpatient setting: Results of 934 patients during up to 10 years' follow-up. Canadian Journal of Diabetes. 2004;28(3):190–195.
729.
Timratana P, El-Hayek K, Shimizu H, Kroh M, Chand B. Laparoscopic Gastric Electrical Stimulation for Medically Refractory Diabetic and Idiopathic Gastroparesis. Journal of Gastrointestinal Surgery. 2013;17(3):461–470. [PubMed: 23288718]
730.
Timratana P, El-Hayek KM, Shimizu H, Kroh M, Chand B. Laparoscopic gastric pacer therapy for medical refractory diabetic and idiopathic gastroparesis. Gastroenterology. 2012;142(5 SUPPL. 1):S1065.
731.
Toseland RW, Labrecque MS, Gobel ST, Whitney MH. An evaluation of a group program for spouses of frail elderly veterans. Gerontologist. 1992;32(3):382–390. [PubMed: 1500004]
732.
Toso C, Shapiro AM, Bowker S, Dinyari P, Paty B, Ryan EA, et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation. 2007;84(5):664–666. [PubMed: 17876283]
733.
Trabucchi A, Faccinetti NI, Guerra LL, Puchulu FM, Frechtel GD, Poskus E, et al. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity. 2012;45(2):137–142. [PubMed: 21875382]
734.
Trento M, Passera P, Borgo E, Tomalino M, Bajardi M, Brescianini A, et al. A 3-year prospective randomized controlled clinical trial of group care in type 1 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases. 2005;15(4):293–301. [PubMed: 16054554]
735.
Trento M, Trinetta A, Kucich C, Grassi G, Passera P, Gennari S, et al. Carbohydrate counting improves coping ability and metabolic control in patients with Type 1 diabetes managed by Group Care. Journal of Endocrinological Investigation. 2011;34(2):101–105. [PubMed: 20440106]
736.
Tridgell DM, Spiekerman C, Wang RS, Greenbaum CJ. Interaction of onset and duration of diabetes on the percent of gad and ia-2 antibody-positive subjects in the type 1 diabetes genetics consortium database. Diabetes Care. 2011;34(4):988–993. [PMC free article: PMC3064062] [PubMed: 21330643]
737.
Tung YC, Lee JS, Tsai WY, Hsiao PH. Evaluation of beta-cell function in diabetic Taiwanese children using a 6-min glucagon test. European Journal of Pediatrics. 2008;167(7):801–805. [PubMed: 17874132]
738.
Tunis SL, Minshall ME, Conner C, McCormick J, I, Kapor J, Yale J-F, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Current Medical Research and Opinion. 2009;25(5):1273–1284. [PubMed: 19366302]
739.
Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26(4):1181–1185. [PubMed: 12663594]
740.
University College London Hospitals. Provider to provider services 2012-2013 tariff. London: Unversity College London Hospitals NHS Foundation Trust; 2012. Available from: https://www​.uclh.nhs​.uk/aboutus/wwd/Documents​/Provider%20to%20Provider​%20Tariff%202012-13.pdf.
741.
Vague P, Selam JL, Skeie S, Leeuw I, Elte JW, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal–bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26(3):590–596. [PubMed: 12610006]
742.
Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal–bolus regimen in Sweden. Scandinavian Journal of Public Health. 2011;39(1):79–87. [PubMed: 20688795]
743.
Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine. 2012;29(3):303–312. [PubMed: 21951030]
744.
Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine and NPH. Advances in Therapy. 2006;23(2):191–207. [PubMed: 16751153]
745.
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. New England Journal of Medicine. 2001;345(19):1359–1367. [PubMed: 11794168]
746.
van der Voort IR, Becker JC, Dietl KH, Konturek JW, Domschke W, Pohle T. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Experimental and Clinical Endocrinology & Diabetes. 2005;113(1):38–42. [PubMed: 15662594]
747.
van Dyk J. Insulin glargine (HOE901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia. Journal of Pediatric Endocrinology and Metabolism. 2000;13(suppl.):34.
748.
van Os N, Niessen LW, Bilo HJ, Casparie AF, van Hout BA. Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. Health Policy. 2000;51(3):135–147. [PubMed: 10720684]
749.
Van Tilburg MAL, McCaskill CC, Lane JD, Edwards CL, Bethel A, Feinglos MN, et al. Depressed mood is a factor in glycemic control in type 1 diabetes. Psychosomatic Medicine. 2001;63(4):551–555. [PubMed: 11485108]
750.
Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews. 2008;(Issue 3) CD006297. [PMC free article: PMC6486116] [PubMed: 18646147] [CrossRef]
751.
Vaughan NJ, Shaw M, Boer F, Billett D, Martin C. Creation of a District Diabetes Register using the DIALOG system. Diabetic Medicine. 1996;13(2):175–181. [PubMed: 8641125]
752.
Vaziri-Sani F, Oak S, Radtke J, Lernmark K, Lynch K, Agardh CD, et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity. 2010;43(8):598–606. [PMC free article: PMC3903401] [PubMed: 20298127]
753.
Venhaus A, Chantelau E. Self-selected unrefined and refined carbohydrate diets do not affect metabolic control in pump-treated diabetic patients. Diabetologia. 1988;31(3):153–157. [PubMed: 3286342]
754.
Vermeulen I, Weets I, Asanghanwa M, Ruige J, Van GL, Mathieu C, et al. Contribution of antibodies against IA-2beta and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care. 2011;34(8):1760–1765. [PMC free article: PMC3142046] [PubMed: 21715527]
755.
Vervoort G, Goldschmidt HM, van Doorn LG. Nocturnal blood glucose profiles in patients with type 1 diabetes mellitus on multiple (> or = 4) daily insulin injection regimens. Diabetic Medicine. 1996;13(9):794–799. [PubMed: 8891454]
756.
Viallon A, Zeni F, Lafond P, Venet C, Tardy B, Page Y, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Critical Care Medicine. 1999;27(12):2690–2693. [PubMed: 10628611]
757.
Vignati L, Anderson JH Jr., Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clinical Therapeutics. 1997;19:1408–1421. [PubMed: 9444449]
758.
Vlad A, Serban V, Sima A, Timar R, Rosu M. The value of basal C peptide and its relationship with pancreatic autoantibodies in young adults with type 2 diabetes mellitus. Romanian Journal of Internal Medicine. 2004;42(2):333–341. [PubMed: 15529624]
759.
Vondra K, Vrbikova J, Sterzl I, Bilek R, Vondrova M, Zamrazil V. Thyroid autoantibodies and their clinical relevance in young adults with type 1 diabetes during the first 12 yr after diabetes onset. Journal of Endocrinological Investigation. 2004;27(8):728–732. [PubMed: 15636424]
760.
Vriesendorp TM, Morelis QJ, DeVries JH, Legemate DA, Hoekstra JB. Early post-operative glucose levels are an independent risk factor for infection after peripheral vascular surgery. A retrospective study. European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery. 2004;28(5):520–525. [PubMed: 15465374]
761.
Wagner A, Risse A, Brill HL, Wienhausen-Wilke V, Rottmann M, Sondern K, et al. Therapy of severe diabetic ketoacidosis. Zero-mortality under very-low-dose insulin application. Diabetes Care. 1999;22(5):674–677. [PubMed: 10332664]
762.
Walter M, McDonald CG, Paty BW, Shapiro AMJ, Ryan EA, Senior PA. Prevalence of autoimmune diseases in islet transplant candidates with severe hypoglycaemia and glycaemic lability: previously undiagnosed coeliac and autoimmune thyroid disease is identified by screening. Diabetic Medicine. 2007;24(2):161–165. [PubMed: 17257278]
763.
Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment. 2004;8(45):iii–41. [PubMed: 15525480]
764.
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment. 2010;14(36):1–248. [PubMed: 20646668]
765.
Webb DJ, Newman DJ, Chaturvedi N, Fuller JH. The use of the Micral-Test strip to identify the presence of microalbuminuria in people with insulin dependent diabetes mellitus (IDDM) participating in the EUCLID study. Diabetes Research and Clinical Practice. 1996;31:93–102. [PubMed: 8792107]
766.
Wehrmann T, Lembcke B, Caspary WF. Influence of cisapride on antroduodenal motor function in healthy subjects and diabetics with autonomic neuropathy. Alimentary Pharmacology and Therapeutics. 1991;5(6):599–608. [PubMed: 1782304]
767.
Wei N, Zheng H, Nathan DM. Empirically Establishing Blood Glucose Targets to Achieve HbA1c Goals. Diabetes Care. 2014;37(4):1048–1051. [PMC free article: PMC3964488] [PubMed: 24513588]
768.
Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. Journal of Clinical Endocrinology and Metabolism. 2013;98(8):3411–3419. [PubMed: 23760624]
769.
Weitgasser R, Schnoll F, Pretsch I, Gruber U. Evaluation of self-monitoring of blood glucose after five years of intensive insulin therapy following a basal–bolus regimen. Diabetologia Croatica. 1994;23(1):13–17.
770.
Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. Journal of Clinical Endocrinology and Metabolism. 2010;95(10):4712–4719. [PMC free article: PMC3050104] [PubMed: 20610599]
771.
Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003;26(11):3074–3079. [PubMed: 14578242]
772.
White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology. 2008;126(12):1707–1715. [PMC free article: PMC2663518] [PubMed: 19064853]
773.
White NH, Waltman SR, Krupin T, Santiago JV. Reversal of abnormalities in ocular fluorophotometry in insulin-dependent diabetes after five to nine months of improved metabolic control. Diabetes. 1982;31(1):80–85. [PubMed: 6759217]
774.
Whitehead C, Lunt H, Pearson JF, Cawood TJ. Is screening for hypothyroidism in the diabetes clinic effective? Practical Diabetes International. 2010;27(3):113–117.
775.
Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724–730. [PubMed: 11919132]
776.
Wiggam MI, O'Kane MJ, Harper R, Atkinson AB, Hadden DR, Trimble ER, et al. Treatment of diabetic ketoacidosis using normalization of blood 3- hydroxybutyrate concentration as the endpoint of emergency management: A randomized controlled study. Diabetes Care. 1997;20(9):1347–1352. [PubMed: 9283776]
777.
Wikblad K, Leksell J, Wibell L. Health-related quality of life in relation to metabolic control and late complications in patients with insulin dependent diabetes mellitus. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 1996;5(1):123–130. [PubMed: 8901375]
778.
Wikblad K, Montin K, Wibell L. Metabolic control, residual insulin secretion and self-care behaviours in a defined group of patients with type 1 diabetes. Upsala Journal of Medical Sciences. 1991;96(1):47–61. [PubMed: 1897062]
779.
Willey KA, Twigg SM, Constantino MI, Yue DK, Turtle JR. Home blood glucose monitoring: How often? Practical Diabetes. 1993;10(1):22–25.
780.
Wilmot-Roussel H, Levy DJ, Carette C, Caillat-Zucman S, Boitard C, Timsit J, et al. Factors associated with the presence of glutamic acid decarboxylase and islet antigen-2 autoantibodies in patients with long-standing type 1 diabetes. Diabetes & Metabolism. 2013;39(3):244–249. [PubMed: 23522731]
781.
Wilson HK, Keuer SP, Lea AS, Boyd AE, III, Eknoyan G. Phosphate therapy in diabetic ketoacidosis. Archives of Internal Medicine. 1982;142(3):517–520. [PubMed: 6802095]
782.
Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, et al. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. Diabetic Medicine. 1990;7(8):736–743. [PubMed: 2147637]
783.
Woo V, Clendenan J. Association of frequency of Self-Monitoring of Blood Glucose (SMBG) and HbA1c in the clinical practice. Diabetes. 2011;60(Suppl.1):A241.
784.
Wright J, Ruck K, Rabbitts R, Charlton M, De P, Barrett T. Diabetic ketoacidosis (DKA) in Birmingham, UK, 2000–2009: an evaluation of risk factors for recurrence and mortality. British Journal of Diabetes and Vascular Disease. 2009;9:278–282.
785.
Wright RJ, Frier BM, Deary IJ. Effects of acute insulin-induced hypoglycemia on spatial abilities in adults with type 1 diabetes. Diabetes Care. 2009;32(8):1503–1506. [PMC free article: PMC2713616] [PubMed: 19487633]
786.
Wu SY, Lung BC, Chang S, Lee SC, Critchley JA, Chan JC. Evaluation of drug usage and expenditure in a hospital diabetes clinic. Journal of Clinical Pharmacy and Therapeutics. 1998;23(1):49–56. [PubMed: 9756112]
787.
Yale JF, Begg I, Gerstein H, Houlden R, Jones H, Maheux P, et al. 2001 Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Hypogyceamia in Diabetes. Canadian Journal of Diabetes Care. 2001;26(1):22–35.
788.
Yamaguchi K, Fukushima H, Uzawa H. Response of human growth hormone, prolactin and thyrotropin to thyrotropin releasing hormone in liver cirrhosis and diabetes mellitus. Endocrinologia Japonica. 1979;26(1):81–88. [PubMed: 108097]
789.
Yamaguchi Y, Chikuba N, Ueda Y, Yamamoto H, Yamasaki H, Nakanishi T, et al. Islet cell antibodies in patients with autoimmune thyroid disease. Diabetes. 1991;40(3):319–322. [PubMed: 1999272]
790.
Yang L, Zhou ZG, Tan SZ, Huang G, Jin P, Yan X, et al. Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults. Annals of the New York Academy of Sciences. 2008;1150:263–266. [PubMed: 19120309]
791.
Yasmin T, Ghafoor F, Malik T, Ruhy N, Khan AU. Pattern of thyroid autoimmunity in type 1 and type 2 diabetics. Journal of the College of Physicians and Surgeons--Pakistan. 2006;16(12):751–754. [PubMed: 17125632]
792.
Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes. 1996;45(12):1729–1733. [PubMed: 8922358]
793.
Yokoyama KK, Cryar AK, Griffin KC, Godley PJ, Woodward BW. Cost-effectiveness of a multidisciplinary diabetes care clinic. Drug Benefit Trends. 2002;14(Suppl. D):36–44.
794.
Yun YS, Lee HC, Park CS, Chang KH, Cho CH, Song YD, et al. Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis. Journal of Diabetes & Its Complications. 1999;13(5-6):288–292. [PubMed: 10765004]
795.
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine. 2000;342:154–160. [PubMed: 10639540]
796.
Zachariah S, Sheldon B, Shojaee-Moradie F, Jackson NC, Backhouse K, Johnsen S, et al. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care. 2011;34(7):1487–1491. [PMC free article: PMC3120205] [PubMed: 21593292]
797.
Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice. 1999;46(3):239–246. [PubMed: 10624790]
798.
Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). Journal of Clinical Endocrinology and Metabolism. 2012;97(10):3759–3765. [PubMed: 22865904]
799.
Zelmanovitz T, Gross JL, Oliveira J, De Azevedo MJ. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care. 2003;21(7):1076–1079. [PubMed: 9653598]
800.
Zhang S, Sun Q, Feng K, Fu Y, Wang O, Ping F, et al. Clinical, biochemical, and immunological characteristics of newly diagnosed nonobese diabetic patients aged 18-45 years in China. Journal of Diabetes and Its Complications. 2012;26(1):40–43. [PubMed: 22226483]
801.
Ziegler D, Merfort F, van AH, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. Journal of Sexual Medicine. 2006;3(5):883–891. [PubMed: 16942532]
802.
Ziegler O, Kolopp M, Got I, Genton P, Debry G, Drouin P. Reliability of self-monitoring of blood glucose by CSII-treated patients with type I diabetes. Diabetes Care. 1989;12(3):184–188. [PubMed: 2702908]
803.
Ziegler O, Kolopp M, Louis J, Musse JP, Patris A, Debry G, et al. Self-monitoring of blood glucose and insulin dose alteration in type 1 diabetes mellitus. Diabetes Research and Clinical Practice. 1993;21(1):51–59. [PubMed: 8253023]
804.
Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. More frequent SMBG is associated with more frequent insulin boluses and lower HbA1c: Baseline results from the ABACUS. Diabetologia. 2012;55(Suppl.1):S425.
805.
Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control: First results from the ABACUS trial. Diabetes Care. 2013;36(11):3613–3619. [PMC free article: PMC3816874] [PubMed: 23900590]
806.
Zoffmann V, Vistisen D, Due-Christensen M. A cross-sectional study of glycaemic control, complications and psychosocial functioning among 18- to 35-year-old adults with Type 1 diabetes. Diabetic Medicine. 2014;31(4):493–499. [PubMed: 24236961]
Copyright © 2015 National Clinical Guideline Centre.
Bookshelf ID: NBK343338

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...